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Interrogating K2P Pharmacology: development and characterization of small-
molecule modulators of two-pore potassium channels 
 
by 
 
Lianne Elizabeth Pope 
 
Abstract:  
Two-pore potassium (K2P) channels are responsible for regulating the resting 
membrane potential of excitable cells. Though K2P channels are heavily implicated in 
disease, no approved therapies exist to specifically target K2P channels. Defined 
pharmacology for these channels has lagged, as K2Ps differ from traditional potassium 
channels in a number of ways. By harnessing these differences, we aim to discover and 
characterize new K2P modulators to aid in the study of this unique channel class. Through 
the structural and functional characterization of small molecule K2P modulators, we will 
facilitate the understanding of how these channels contribute to physiology and disease.  
The introduction of this thesis aims to define and describe the scope of K2P 
pharmacology, with a specific focus on TREK family modulation. High throughput 
methods for identifying new classes of TREK family modulators are reviewed, and a 
synthesis of the selectivity of small-molecule TREK family modulators has been compiled, 
with special attention to those compounds for which structural information has been 
elucidated. In chapter two, the action and selectivity of K2P activator BL-1249 is presented 
and, using a chimeric functional approach, subtle differences between K2P2.1 (TREK-1) 
and K2P4.1 (TRAAK) channels and their differential response to BL-1249 were pinpointed 
to specific areas involving M2 and M4 helices. This work highlights how channels within 
K2P families can differ from one another in their pharmacological profiles and how 
  vii 
selective molecules can help to tease apart these important differences. Chapter three 
presents structural and functional studies of polyruthenium amine inhibitors of K2Ps and 
creation of a ruthenium red super-binder with low nanomolar efficacy. Through our 
studies, we define the mechanism of polyruthenium amine inhibitors as an electrostatic 
block positioned above by coordinating acidic residues. Furthermore, we provide a 
template for future development of K2P modulators which may target this novel binding 
site. From these and other recent studies, a multi-site model for K2P pharmacological 
regulation has emerged and future work will require precise dissection to establish how 
each of these sites may preferentially affect gating in TREK, and more broadly, all K2Ps. 
Finally, chapter four presents the synthetic modulation of a protein-protein interaction 
(PPI) using stapled peptides in a different context, departing from a focus on K2P channels 
onto another voltage-gated ion channel (VGIC) family member, voltage-gated calcium 
channels (CaV). Stapled peptide mimics of the a-interacting domain (AID) were found to 
inhibit the high affinity interaction of the channel domain (CaVa) with its cytosolic subunit 
(CaVb) to affect calcium channel properties. Establishing and improving the modulation 
of this type of PPI informs the future development of inhibitors of K2P interactions with 
important cellular partners. 
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Chapter 1 : Introduction 
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K2P channels: pharmacological relevance and therapeutic potential 
Ion channels facilitate the flow of electricity in all neuronal processes, manifesting 
the physiology of thought, movement, mood and sensation1. In all organisms, a suite of 
ion channels controls cellular action and excitability and among these, potassium ‘leak’ 
channels are responsible for the setpoint and maintenance of cellular resting potential in 
between neuronal pulses (Figure 1.1A)2–4. Potassium (K+) ion channels with two-pore 
domains (K2P) are part of the voltage-gated ion channel (VGIC) superfamily5 (Figure 1.1B) 
and are named K2P for their unique architecture, which distinguishes them amongst other 
K+ channels, the largest and most diverse channel family (shaded red in figure). 
K2P channels are distinct in many ways from classical potassium channels. K2Ps 
feature a dimeric architecture, with one subunit bearing two pore-forming helical 
sequences (P1 and P2) flanked by four transmembrane helices, M1-M4 (Figure 1.2A, 
left)6. Other notable structural features of K2P channels include an extracellular cap (CAP) 
domain that is also absent in canonical K+ channels. Each subunit bears sequences at 
both the N and C termini that are likely to be unstructured. The four pore helices (P1 and 
P2 from each subunit) combine to form a potassium selective filter capable of outward K+ 
conduction in under most physiological membrane potentials (Figure 1.2A, right)7. In 
further contrast to canonical K+ channels, K2P channels lack an inner gating bundle 
crossing and have been shown to gate exclusively through the selectivity filter ‘C-type’ 
gate8–12. Exogenous stimuli8,13 are integrated through this common gating mechanism, 
finely tuning the cellular leak current to affect cellular excitability. In fact, such aptitude for 
external modulation is a defining feature of this unique channel class and is crucial to the 
function of these channels in a cellular context. 
  3 
 
Since the first characterization of K2P channels over twenty years prior7,14, fifteen 
mammalian K2Ps have been identified and grouped into six families according to 
sequence similarity and characteristic functional properties2,15. Despite sharing an overall 
similar topology, these families, including TWIK, TREK, TASK, THIK, TALK, and TRESK 
(Figure 1.2B), respond characteristically to a unique set of stimuli ranging widely from 
physical (external and internal pH, temperature, and mechanical stretch) to chemical 
(volatile anesthetics and anti-depressants, lipids, polyunsaturated fatty acids (PUFAs)) 
and can even be mediated by local protein-protein interactions (14-3-3, G-proteins, 
Protein Kinase A/C)3,16,17. Given such an important array of modalities, it is unsurprising 
that mis-regulation of K2Ps is often associated with disease, ranging from disorders of the 
nervous systems like migraine18, Birk-Barel syndrome19, ischemia20 and facial gestalt21 to 
disorders of cardiovascular systems resulting in arrythmias22–26 and hypertension27. 
Further biological and mechanistic study of these channels has been challenging due to 
their resistance to classical potassium channel blockers and general lack of specific 
chemical tools3,28–32. Despite their potential as therapeutic targets, there are no approved 
drugs which specifically target K2Ps. Combined with the need for further biological study, 
there is an urgent need for the development and characterization of novel, K2P-specific 
modulators and a campaign for such molecules has begun in earnest. 
The TREK family: a model K2P system 
The most extensively studied K2P family, the TREK subfamily is comprised of 
K2P2.1 (TREK-1), K2P10.1 (TREK-2) and K2P4.1 (TRAAK). These channels are thermo-, 
mechano-, and lipid sensitive and have been implicated as important therapeutic targets 
for pain, ischemia, and depression15,28,30,32,33. TREK family channels have evolved as 
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sensors for numerous physical and chemical stimuli, and their regulation by pH, 
temperature, stretch and lipids have been well characterized8,9,34,35. These channels are 
readily expressed in heterologous systems and their experimental adaptability has led to 
this family becoming an important model for understanding K2P channel biophysics and 
in realizing its pharmacological potential. TREK family channels have also been shown 
to heterodimerize36–38, forming channels with hybrid properties and increasing functional 
diversity in cells that express more than one type of K2P channel. Additionally, this class 
of K2P channels is the most structurally elucidated, with recent structures emerging of all 
three members in various states of activity39–44. With the clearest picture and robustness 
of functional characterization, this family has benefited the most in terms of the 
development of specific and potent chemical modulators45–48, the subject of which has 
been reviewed extensively3,17,49.  
 TREK family channels are found throughout the central nervous system, especially 
in the periphery (dorsal root ganglion50, nodes of Ranvier51,52), and are known to be 
regulated at both the transcriptional (via alternative translation initiation36,37,53,54) and 
translational (through post-translational modification3,17,55) levels. In terms of sequence 
similarity, K2P2.1 (TREK-1) and K2P10.1 (TREK-2) bear the highest similarity to each other 
(~65%)38,56–58 and are only moderate similar to K2P4.1 (TRAAK) (~40%) – this similarity 
is also structurally obvious39–44. Despite their structural and functional similarities, TREK 
family channels differ in important ways and likely interact with different partners in distinct 
cellular and developmental contexts, especially at channel regions which differ greatly in 
sequence similarity, namely the N and C termini. Understanding and capitalizing on these 
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differences will continue to lead to the development of subtype specific chemical 
modulators for precision pharmacology. 
Intriguingly, both activation and inhibition of TREK have been proposed as 
mechanisms for affecting distinct therapeutic outcomes. Activation of TREK channels 
drives the membrane potential closer to the equilibrium potential of K+, resulting in 
reduced cellular excitability – this would likely have an antinociceptive effect in the 
periphery where many of these channels reside30. On the other side of the spectrum, 
K2P2.1 (TREK-1) knockout mice have been shown to be resistant to depression and 
K2P2.1 (TREK-1) inhibitors like spadin and norfluoxetine have shown some promising 
efficacy in mouse models for depression49,59,60. Pharmacologically relevant antipsychotics 
have also been reported to inhibit K2P2.1 (TREK-1). Physiologically, inhibiting 
K2P2.1 (TREK-1) would result in a less negative resting potential, but more work is needed 
to understand how the cellular consequences of inhibiting this channel can result in 
modulation of disease state. 
Discovering new chemical modulators of TREK channels 
TREK family channels are clearly interesting and novel targets for therapeutics, 
and as biologically important sensors, have a wide array of natural ligands and 
metabolites which are known to modulate channel activity. These natural ligands (lipids, 
volatile anesthetics) can be hard to work with in vitro and may be unadaptable between 
experimental systems, underscoring a need to generate new chemical matter to expand 
on our knowledge of K2P modulation. In the development of new chemical modulators, 
many studies have modified natural effectors like caffeic acid to produce more potent 
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caffeate esters with more interesting and relevant pharmaceutical properties46,48. Spadin, 
although not a small-molecule, is a naturally derived peptide from the membrane protein 
Sortilin that has been suggested to have some efficacy in mouse models of 
depression49,59,60. Extensive work has been done to characterize the inhibitory effect of 
spadin on K2P2.1 (TREK-1), and effort has been made to improve the peptide scaffold to 
alter its in vivo efficacy and drug-like properties.  
Given the potential therapeutic relevance, it is no surprise that researchers, 
especially pharmaceutical companies, have conducted a number of high throughput 
screens (HTS) resulting in chemical matter capable of targeting TREK family channels. 
At least a few of the known molecules affecting this family were results of screening 
campaigns, especially molecules like BL-124961 or ML335 and ML40242, which have 
industrial origins prior to their entry in the literature. Early efforts to screen in industry often 
relied on monitoring the phenotypic change of a disease-relevant cell-type61,62, especially 
since molecular targets were and continue to be challenging to isolate for screening. 
The first example of one such campaign was the discovery of ML67 and ML45 
series K2P modulators from a novel, yeast-based HTS platform45. In this assay, yeast were 
engineered such that survival (potassium transport) was linked to a K2P of interest, in this 
case K2P2.1 (TREK1). After screening a library of over 100,000 compounds, researchers 
identified both activators (ML67) and inhibitors (ML45) which were validated using 
electrophysiology and, in the case of ML67, improved using structure activity relationships 
(SAR) to ML67-33 (EC50 = 36.3 ± 1 μM). Neither ML67 or ML45 class modulators display 
selectivity between the three TREK family members. 
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Other high-throughput screens against K2Ps have attempted to capitalize on ion 
flux as a readout for channel modulation, followed by electrophysiological validation after 
identification of hit compounds. Thallium and rubidium flux assays have been utilized in 
the channel field to identify new chemical matter63 and in the context of K2Ps, such an 
assay has recently produced compounds with unique properties64. Dadi et al engineered 
a K2P2.1 (TREK-1) expressing cell-line and after screening over 76,000 compounds, 
report the discovery of several new activators and inhibitors, as well as new bioactive 
lipids like 11-deoxyprostaglandin F2a (11-deoxy PGF2a). All of the inhibitors they identified 
were non-selective between K2P2.1 (TREK-1) and K2P10.1 (TREK-2), though authors do 
not report inhibition of K2P4.1 (TRAAK).  
Su et al take a different approach to flux-based HTS, coupling K+ efflux to H+ influx, 
reported as fluorescence by a H+ binding dye in a cell-free system designed to produce 
binders to purified protein47 reconstituted in liposomes. Using their liposome flux assay 
(LFA) platform, they screened 300,000 compounds and report two novel K2P4.1 (TRAAK) 
inhibitors that were subsequently validated using electrophysiology. Though the authors 
do not report using this platform to identify any K2P4.1 (TRAAK) activators, they did report 
new activator discovery for other K+ channels, demonstrating the adaptability of this high-
throughput platform. TREK family selectivity of these two inhibitors is not reported, 
however these inhibitors do seem to be able to discriminate between at least a few more 
distantly related members of the mammalian K2Ps. 
Broadly, all high throughput screening systems developed to identify TREK family 
modulators to date have yielded both activators and inhibitors, with wide selectivity and 
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efficacy profiles resulting from each screen. The obvious advantage of screening is the 
vast amount of chemical space that may be searched for new modulators, though 
electrophysiological validation is always necessary once hits have been identified. 
Attempts at virtual screening have shown some promise65, but are often limited to 
searching against known binding sites, precluding modulation through any channel state 
not crystallographically observed. As more molecules are identified, it will be important to 
characterize fully the selectivity and efficacies of these new molecules in order to unpack 
their unique molecular mechanisms, aiding improvement of these new molecules as 
potential therapies and tools for biological discovery. 
Pharmacological selectivity of TREK modulators, with structural perspectives 
Extensive reviews have been published on the subject of K2P 
pharmacology3,30,32,49, up to and including a particularly thoughtful and thorough entry17, 
detailing broadly the important chemical modulators, with a particular focus on the 
molecular mechanisms governing K2P modulation by small molecules. What has emerged 
as most relevant to this thesis, however, has been the study of small molecule selectivity 
between TREK family members, as such selectivity studies can shed light on key 
molecular differences in these closely related channels, ultimately leading to a more 
powerful chemical toolset for biological study and therapeutic discovery.  
In general, small molecule selectivity between TREK family members is rare and 
limited to only a few classes of molecules (Figure 1.3). Many compound classes exhibit 
specificity for this mechanosensitive family but are not selective among them; examples 
include 2-APB66, ML67 and ML4545. Some compounds are weakly selective amongst 
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family members, indicating subtle differences in compound binding sites and presumably 
impaired propagation of signaling to the C-type gate. The fenamate class is one such 
example, whose principal member, BL-1249, is ~10-fold selective for K2Ps2.1 (TREK-1) 
and 10.1 (TREK-2) over K2P4.1 (TRAAK) and seems to be able to very weakly activate 
more distantly related K2Ps and potassium channels through a common mechanism67. In 
our study, we leveraged BL-1249’s small window of selectivity between K2P2.1 (TREK-1) 
and K2P4.1 (TRAAK), shedding light on important differences between K2P2.1 (TREK-1) 
and K2P4.1 (TRAAK) leading to differential BL-1249 response, the results and discussions 
of which are detailed in chapter 2 of this thesis. 
A detailed understanding of the molecular differences leading to subtype specificity 
in TREK family channels has been enabled largely by the few structures we have of 
compounds bound to various family members41–43. Perhaps the most compelling example 
of this is the selectivity of ML335 and ML402 for K2Ps2.1 (TREK-1) and 10.1 (TREK-2) 
over K2P4.1 (TRAAK)42. This class of activators was found to stabilize the C-type gate by 
binding to a cryptic site not observed in the K2P2.1 (TREK-1) unbound state. Paired with 
the functional observation of activator selectivity between K2P2.1 (TREK-1) and 
K2P4.1 (TRAAK), structural analysis identified a key difference between the channels in 
the compound binding site, a lysine in K2P2.1 (TREK-1), involved in a key cation-pi 
interaction between the protein and the molecule. Mutation of the equivalent residue in 
K2P4.1 (TRAAK) (Q to K) renders the channel sensitive to ML335/402 while the K to Q 
mutation in K2P2.1 (TREK-1) kills activation response. 
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Generally, if a compound class displays selective properties, K2P4.1 (TRAAK) is 
found to be the odd channel out. This is consistent with the relatively low overall sequence 
homology between K2Ps2.1 (TREK-1) and 10.1 (TREK-2) versus K2P4.1 (TRAAK). In 
addition to the activator classes detailed above, there are a few classes of small 
molecules which are selective for K2Ps2.1 (TREK-1) and 10.1(TREK-2) over 
K2P4.1 (TRAAK), including activators GI-53015968 and natural product aristolochic acid69, 
and inhibitors like tricyclic antipsychotics70 and fluoxetine/norfluoxetine, the latter of 
whose structure bound to K2P10.1 (TREK-2) established the ‘fenestration’ site as an 
important nexus that can be targeted for inhibition in K2Ps2.1 (TREK-1) and 
10.1 (TREK-2)41. Additionally, recent structural studies indicate BL-1249 is also targeted 
to the fenestration site43, coordinating ion flow from below the selectivity filter, and 
establishing that both activators and inhibitors may share the same binding sites but can 
have opposite modes of regulation. Fenestration site selectivity in K2Ps2.1 (TREK-1) and 
10.1 (TREK-2) over K2P4.1 (TRAAK) might also indicate that K2P4.1 (TRAAK) has a 
fenestration site which may be hard to target. Consequently, carefully targeting this 
structural difference might yield K2P4.1 (TRAAK)-specific modulators. 
Rarer still are compound classes capable of discriminating between 
K2P2.1 (TREK-1) and K2P10.1 (TREK-2), likely because their high homology makes 
discrimination between these similar channels a challenging task. As mentioned 
previously, Dadi et al reported a series of inhibitors which could not discriminate between 
K2P2.1 (TREK-1) and K2P10.1 (TREK-2)64. However, in their screen the authors also 
identified activators which could discriminate between the two channels and were found 
to be selective for K2P10.1 (TREK-2) over K2P2.1 (TREK-1). Even more surprising, the 
  11 
 
authors describe one activator T2A3 that seems capable of activating K2P10.1 (TREK-2) 
while simultaneously inhibiting K2P2.1 (TREK-1). Structural studies which aim to 
understand the molecular origin of this mode-switching behavior could uncover key 
differences between K2Ps2.1 (TREK-1) and 10.1 (TREK-2) that could be exploited for 
selectivity improvements. 
Lastly, K2P10.1 (TREK-2) but not K2P2.1 (TREK-1) bears sensitivity to inhibition by 
ruthenium red (RuR). Other channels, outside the TREK subfamily, are also sensitive to 
RuR, including K2P9.1 (TASK-3). Through our own structural studies44, we have 
uncovered the molecular mechanisms governing this interaction using a K2P2.1 (TREK-1) 
channel bearing a mutation at the base of the CAP region of the channel, I110D. This 
mutation renders K2P2.1 (TREK-1) sensitive to RuR71 and is natively an aspartate in 
K2P10.1 (TREK-2) and glutamate in K2P9.1 (TASK-3). This local negative charge positions 
ruthenium red in just the right position (deemed the ‘keystone’ inhibitor site) to provide an 
electrostatic block against outward flow of potassium. K2P4.1 (TRAAK) is also natively 
sensitive to RuR; however, the binding mode of RuR is likely different, as K2P4.1 (TRAAK) 
lacks this stabilizing negative charge at the base of its CAP region. Our studies, further 
detailed in chapter three, show that is possible to coordinate ruthenium red in the 
keystone inhibitor site through the synthetic introduction of other local negative charge 
close to the keystone site. Future structural studies of K2P4.1 (TRAAK) in complex with 
RuR would help to fully clarify the mechanisms by which K2Ps are inhibited by RuR. 
Although K2P4.1 (TRAAK) was the first TREK family K2P to be structurally characterized39, 
it remains the only channel in the family lacking any compound-bound structures. 
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Modulation of protein-protein interactions – lessons from voltage-gated calcium 
channels (CaV) 
Like most ion channels, K2Ps are known to interact with and are regulated by a wide 
array of cellular partners3,16,17 and certain protein-protein interactions (PPIs) have been 
implicated as potential nodes of regulation, especially those involved in channel 
trafficking72,73 and assembly37. Targeting PPI interfaces with small molecules can be 
challenging due to the large surfaces involved in protein-protein recognition and no 
therapies have yet been developed to specifically target these nodes in the context of 
K2Ps or in any other type of channel. Voltage-gated calcium channels (CaV), distant 
relatives of K2P channels (highlighted blue, Figure 1.1B), have been used as a model for 
the development of channel PPI inhibitors74 and the results from such studies are detailed 
in chapter four. By targeting the high affinity interaction of the pore-domain (CaVa) and its 
cytosolic subunit (CaVb) via the  a-interaction domain (AID), stapled AID peptide mimetics 
are capable of disrupting transient interactions between CaVa and CaVb in a b isoform-
specific manner.  
The development of these inhibitory peptides has only been possible due to the 
extensive characterization of this critical protein-protein interaction, involving functional, 
biophysical and structural characterization of the b-subunit in complex with the a-subunit 
peptide derivatives74–79. Designing such regulators for K2P PPIs will require a similar level 
of characterization and the consequences of synthetically disrupting such interactions is, 
as of yet, completely unknown. 
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Emergence of a poly-site model for K2P modulation – future directions 
With the availability of structural information, it has at last been possible to understand 
clearly and characterize molecular mechanisms of action for an initial set of small 
molecule modulators of TREK family K2P channels. Though functional experiments have 
been important for establishing channel biophysics and the molecular mechanisms of 
polymodal stimulation, structure-function studies have enabled the precise enhancement 
of molecular interactions, providing a template for the improvement of each class of 
structurally characterized activator. What has emerged is a poly-site model of K2P 
pharmacology (Figure 1.4), whereby K2Ps may be regulated by small molecules at least 
three sites, above (keystone), at the level of (cryptic pocket behind the filter) or below the 
selectivity filter (fenestration site). It should be noted, the modulatory lipid binding site of 
bioactive molecules like PIP2 has not yet been shown to be targetable by small molecules, 
but this may change as scientific interest and capacity for modulator screening grows. 
This picture remains incomplete but will resolve in time as more structural information 
becomes available. In particular, cryo-electron microscopy (cryo-EM) will enable the 
structural characterization of K2P channels in complex with important cellular partners, 
information which has been lacking in K2P crystallographic studies. 
Future work aims to capitalize on the known modulator sites in the discovery of new 
chemical matter with the potential to utilize known sites as anchors for affecting function 
in novel and useful ways. Such molecules may be cleverly engineered to block or 
enhance various physical and chemical stimuli or even to chemically modify the channel 
for study in more complex cell types and tissues.   
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Figure 1.1 | A suite of ion channels controls the action potential 
A Typical action potential, with each stage controlled by unique ion channels. K2P 
channels control the resting potential (starred) – figure adapted from Molecular Devices80 
B Dendrogram of voltage-gated ion channels (VGIC), with potassium channels shaded in 
red. K2P channels are denoted by star. Figure adapted from Guide to Pharmacology81 
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Figure 1.2 | K2P channels are grouped according to structure and function 
A Diagram of K2P channel embedded in a membrane. One subunit is shown on the left. 
Extracellular CAP region shown in green. Helices M1-M4 (blue and purple) are separated 
by two pore domains P1 and P2, (pink). Dimer is depicted on the right. Figure adapted 
from Feliciangeli, 20143. B K2P dendrogram. Families are grouped according to common 
stimuli and sequence similarity.  
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Figure 1.3 | Selectivity profiles of small molecule modulators of TREK channels 
Small molecules reported to affect TREK family channels are grouped according to their 
ability to discriminate between channels (indicated in bold). Asterisks indicate report of 
selectivity without complete electrophysiological characterization.  
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Figure 1.4 | Unified model for K2P poly-site pharmacology 
Cartoon of K2P channel showing all structurally defined small molecule binding sites 
centered around the ‘C-type’ gate K+ ions (purple), including Keystone inhibitor site 
(maroon), K2P modulator pocket (orange), fenestration site (green) and modulatory lipid 
site (light blue) 
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Chapter 2 : Protein and chemical determinants of BL-1249 action and selectivity 
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Abstract 
K2P potassium channels generate leak currents that stabilize the resting membrane 
potential of excitable cells. Various K2Ps are implicated in pain, ischemia, depression, 
migraine, and anesthetic responses, making this family an attractive target for small 
molecule modulator development efforts. BL-1249, a compound from the fenamate class 
of non-steroidal anti-inflammatory drugs is known to activate K2P2.1 (TREK-1), the 
founding member of the thermo- and mechanosensitive TREK subfamily; however, its 
mechanism of action and effects on other K2Ps are not well-defined. Here, we 
demonstrate that BL-1249 extracellular application activates all TREK subfamily 
members but has no effect on other K2P subfamilies. Patch clamp experiments 
demonstrate that, similar to the diverse range of other chemical and physical TREK 
subfamily gating cues, BL-1249 stimulates the selectivity filter ‘C-type’ gate that controls 
K2P function. BL-1249 displays selectivity among the TREK subfamily, activating K2P2.1 
(TREK-1) and K2P10.1 (TREK-2) ~10-fold more potently than K2P4.1 (TRAAK). 
Investigation of mutants and K2P2.1 (TREK-1)/ K2P4.1 (TRAAK) chimeras highlight the 
key roles of the C-terminal tail in BL-1249 action and identify the M2/M3 transmembrane 
helix interface as a key site of BL-1249 selectivity. Synthesis and characterization of a set 
of BL-1249 analogs demonstrates that both the tetrazole and opposing tetralin moieties 
are critical for function, whereas the conformational mobility between the two ring systems 
impacts selectivity. Together, our findings underscore the landscape of modes by which 
small molecules can affect K2Ps and provide crucial information for the development of 
better and more selective K2P modulators of the TREK subfamily. 
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Introduction 
K2P (KCNK) potassium channels are members of the voltage-gated ion channel 
(VGIC) superfamily, make ‘background’ or ‘leak’ potassium channels that are responsible 
for the maintenance of cellular resting potential, and play an important role in regulating 
cellular excitability1-3. There are fifteen K2P subtypes that form six functionally distinct 
subfamilies. All K2Ps comprise a dimer of subunits that each bear four transmembrane 
helices and two selectivity filter sequences1, 4-7. In contrast to other VGIC superfamily 
members, the K2P channel selectivity filter forms the principle gate that controls channel 
function, known as the ‘C-type gate’, rather than an intracellular barrier formed by the 
pore-lining helices6, 8-12. The activity of various K2P subtypes has been linked to a variety 
of physiological and pathological processes including pain13-15, anesthetic responses16, 
17, arrhythmia18, ischemia16, 19, 20, depression21, and migraine22, 23. Yet, despite these 
biological links, a paucity of K2P-selective small molecule modulators has limited 
mechanistic and physiological studies1, 24, 25. Recent advances demonstrate that it is 
possible to develop subtype-selective K2P small molecule modulators6, 14, 26-30. Such 
compounds and the knowledge of how they engage K2Ps to modulate function open a 
path towards elaborating new K2P-specific pharmacological tools that can enlighten 
channel gating mechanisms and that have potential to provide new leads for issues such 
as pain and ischemia25, 31, 32. 
The TREK K2P subfamily, comprising K2P2.1 (TREK-1), K2P10.1 (TREK-2), and 
K2P4.1 (TRAAK), is regulated by diverse inputs that include temperature, stretch, pH, and 
lipids1-3, and stands out as the most structurally elucidated K2P subfamily4, 6, 7, 33-35. TREK 
subfamily structures include examples of both inhibitor:channel7 and activator:channel 
  33 
 
complexes6 that highlight two points of control that can be influenced by small molecules: 
the transmembrane helices7 and the K2P modulator pocket6. Although these examples 
show how a small molecule can engage with the K2P channel architecture to impact 
function, whether other reported TREK activators14, 26, 28, 36 act via the transmembrane 
domains, the K2P modulator pocket, or affect other K2P channel elements remains to be 
elaborated. 
Although not selective for K2Ps, a number of fenamates, substituted derivatives of 
anthranilic acid37, activate members of the mechanosensitive TREK K2P subfamily38, 39. In 
particular, BL-1249, [(5,6,7,8-Tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-
amine, stimulates K2P2.1 (TREK-1)-like currents in bladder smooth muscle cells39 and 
activates both K2P2.1 (TREK-1) 18, 40 and K2P10.1 (TREK-2) 7. BL-1249 action is occluded 
by mutations that stabilize the C-type gate40 and activation by BL-1249 has been shown 
to reverse the functional effects of a K2P2.1 (TREK-1) genetic mutation implicated in right 
ventricular outflow tract (RVOT) tachycardia having a compromised ion selectivity18. 
Nevertheless, how BL-1249 stimulates K2P activity and which elements of BL-1249 are 
crucial for its stimulatory effects have not yet been defined. 
Here, we investigate the mechanism of action of BL-1249. Our studies show that this 
compound is a selective agonist of the TREK subfamily when applied extracellularly, 
having preferential action on K2P2.1 (TREK-1) and K2P10.1 (TREK-2) over K2P4.1 
(TRAAK) and establish that its mechanism of action relies on gating at the selectivity filter 
C-type gate. Studies of a series of K2P2.1 (TREK-1)/K2P4.1 (TRAAK) chimeras and 
mutants indicate the M2/M3 helices are key to BL-1249 action and identify residues in M2 
that contribute to subtype selectivity. These findings indicate that BL-1249 acts at a 
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separate site from the site of action of a structurally characterized activator, ML335, that 
directly stimulates the C-type gate via the K2P modulator pocket6. Investigation of the 
functional properties of a set of BL-1249 analogs with respect to K2P 2.1 (TREK-1) and 
K2P 4.1 (TRAAK) show that both the acidic and tetralin moieties contribute to the 
stimulatory action of BL-1249 and indicate that the mobility of the two aryl rings relative 
to each other is key to the selective action of BL-1249 on K2P 2.1 (TREK-1). 
Results 
BL-1249 external application differentially and selectively activates 
mechanosensitive K2Ps 
BL-1249 activates K2P2.1 (TREK-1) 18, 40 and K2P10.1 (TREK-2) 7 but its effects on 
other K2Ps have not been characterized. Hence, we sought to define how BL-1249 
affected the two channels most closely related to K2P2.1 (TREK-1), K2P10.1 (TREK-2) and 
K2P4.1 (TRAAK), as well as representative members of the other K2P subtypes: K2P1.1 
(TWIK-1), K2P3.1 (TASK-1), K2P5.1 (TASK-2), K2P9.1 (TASK-3), K2P13.1 (THIK-1), and 
K2P18.1 (TRESK) (Figure 1A-B). Two-electrode voltage clamp (TEVC) currents measured 
from Xenopus oocytes expressing each of the target channels showed clear activation 
responses after extracellular application of 10 µM BL-1249 for only K2P2.1 (TREK-1) and 
K2P10.1 (TREK-2). Measurement of the dose-response curves for these channels (Figure 
1C) revealed similar EC50s (5.5 ± 1.2 µM and 8.0 ± 0.8 µM for K2P2.1 (TREK-1) and 
K2P10.1 (TREK-2), respectively). 10 µM BL-1249 weakly stimulated K2P4.1 (TRAAK) in 
agreement with observations by Mathie and colleagues28. Measurement of the dose-
response uncovered a robust response at higher concentrations that indicated a ~10-fold 
reduction in the K2P4.1 (TRAAK) EC50 value relative to the other two TREK subfamily 
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members (EC50= 48 ± 10 µM, although complete saturation of the response could not be 
reached due to BL-1249 solubility limits, cf. Table 1) (Figure 1C). In order to test if the 
original 10 µM assay had missed BL-1249 effects in other K2Ps, we tested concentrations 
of BL-1249 up to the solubility limit (~80 µM) against the other K2P subfamily 
representatives. Despite the higher concentrations of BL-1249, we failed to find evidence 
for activation of the other K2P subfamily representatives (Figure 1D). Thus, the data show 
that extracellular application of BL-1249 activates all members of the mechano- and 
thermo-sensitive TREK subfamily while sparing the other subfamilies and shows 
selectivity for K2P2.1 (TREK-1) and K2P10.1 (TREK-2) over K2P4.1 (TRAAK). 
BL-1249 activates the K2P2.1 (TREK-1) C-type gate 
Diverse types of physical and chemical stimuli activate K2P2.1 (TREK-1) by stabilizing 
the C-type gate and switching the channel into a ‘leak’ mode that is characterized by a 
loss of outward rectification of the potassium current6, 8. Accordingly, we used inside-out 
patch clamp experiments of K2P2.1 (TREK-1) expressed in HEK293 cells to test whether 
BL-1249 acts on the C-type gate. Application of 1 µM BL-1249 caused a clear loss of 
rectification similar to the effects reported for both physical and chemical activators of 
K2P2.1 (TREK-1) (Figure 2A-E) 6, 8. Additionally, TEVC studies of the effects of BL-1249 
on K2P2.1 (TREK-1) channels bearing mutations that activate the C-type gate, G137I and 
W275S6, 10, 41 demonstrated that these channels were insensitive to BL-1249 (Figure 2F). 
Together with previous single point concentration studies showing the insensitivity of 
K2P2.1 (TREK-1) W275S in mammalian cells40, our data provide definitive evidence that 
BL-1249 activates K2P2.1 (TREK-1) by stimulating the C-type gate. Thus, this compound 
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fits the mechanistic paradigm shared by varied types of activators including mechanical 
stretch, pH, lipids, and small molecules6, 8. 
K2P C-terminal tail is necessary for BL-1249 action but is not the sole determinant 
of channel responsiveness  
Gating stimuli detected by sensors in various parts of the channel converge on the K2P 
selectivity filter C-type gate6, 8, 10, 12, 35. Because the C-terminal tail is the sensor for K2P2.1 
(TREK-1) activation by both physiological41-46 and chemical45, 47 activators, we asked 
whether uncoupling the C-terminal tail from the channel using a triple-glycine mutant at 
the M4/C-terminal tail junction, K2P2.1 (TREK-1)GGG 41, impacted the BL-1249 response. 
TEVC dose response studies of K2P2.1 (TREK-1)GGG showed that the effects of BL-1249 
were significantly blunted relative to wild-type channels (EC50 = 19 ± 1 µM) (Figure 3A). 
This result contrasts previous studies of the small molecule activator ML67-33 26 for which 
uncoupling the C-terminal tail had no effect, and suggests that unlike ML67-33, the C-
terminal tail plays a role in mediating the BL-1249 response. 
K2P2.1 (TREK-1) C-terminal truncations have been shown to reduce potentiation by 
other activating stimuli42, 48. Hence, to probe the role of the C-terminal tail in the BL-1249 
response further, we examined the effects of C-terminal tail truncations at residue 322, 
K2P2.1 (TREK-1)D322, equivalent to a previously described mutant called Δ8948 and at 
residue 308, K2P2.1 (TREK-1)D308. Measurement of the dose-response curves for BL-
1249 showed that these changes resulted in progressively reduced responses (EC50 = 
26 ± 8 µM and 35 ± 8 µM for K2P2.1 (TREK-1)D322 and K2P2.1 (TREK-1)D308, respectively) 
(Figure 3B). 
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Given the importance of the C-terminal tail for the BL-1249 response and the fact that 
the C-terminal tails of K2P2.1 (TREK-1) and K2P4.1 (TRAAK) vary substantially (17.6% 
sequence similarity, 13.5% identity), we wondered if these differences could contribute to 
the different potencies observed in K2P2.1 (TREK-1) and K2P4.1 (TRAAK) BL-1249 
responses. To test this possibility, we made chimeras that swapped the C-terminal tail 
between K2P2.1 (TREK-1) and K2P4.1 (TRAAK), TREK-1/AAK_T and TRAAK/EK_T. The 
TREK-1/AAK_T chimera yielded channels having responses similar to K2P2.1 (TREK-1) 
(EC50 = 7.7 ± 0.6 μM and 5.5 ± 1.2 μM for TREK-1/AAK_T and K2P2.1 (TREK-1), 
respectively) (Figure 3C). By contrast, swapping the K2P2.1 (TREK-1) C-terminal tail onto 
K2P4.1 (TRAAK), TRAAK/EK1_T, increased the sensitivity of K2P4.1 (TRAAK) core to 
BL-1249 by ~2-fold (EC50 = 23 ± 4 μM and 48 ± 10 μM, for TRAAK/EK1_T and 
K2P4.1 (TRAAK) respectively) (Figure 3D). Despite this modest change, it is clear that the 
C-terminal tail alone is not sufficient to endow the K2P4.1 (TRAAK) core with a 
K2P2.1 (TREK-1)-like BL-1249 response. Although the C-terminal tail is not a major locus 
for the selective actions of BL-1249, the strong impact that uncoupling the C-terminal tail 
from the core channel and C-terminal tail truncations has on the K2P2.1 (TREK-1) 
response to BL-1249 indicate that this channel element is an important factor that allows 
channel activation by BL-1249. 
Multiple transmembrane regions contribute to BL-1249 activation  
To look for other elements that might contribute to BL-1249 responses, we constructed 
a set of K2P2.1 (TREK-1)/K2P4.1 (TRAAK) chimeras in which an increasing amount of one 
channel was spliced with the other. For the purposes of nomenclature, the channels are 
named using the parent N-terminal portion and the C-terminal chimera junction even 
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though the chimera set forms a continuum spanning the two wild type channels (Figure 
4A). For example, TREK-1/AAK M4-C bears the K2P2.1 (TREK-1) sequence up to the 
junction with M4, whereas TRAAK/EK-1 M2-C bears K2P4.1 (TRAAK) up to the junction 
with M2 even though the largest portion of both of these channels comes from 
K2P2.1 (TREK-1). 
TEVC experiments showed that all of the chimeras formed functional channels 
(Figures S1-S2). To test the ability of the chimeras to report on channel determinants for 
compound action, we examined the responses of the chimeras to two previously 
characterized activators, ML335 a compound that selectively activates K2P2.1 (TREK-1) 
but not K2P4.1 (TRAAK) 6 and ML67-33 an activator showing no clear preference for either 
channel26. The chimeras showed an essentially binary response to ML335 that was 
entirely dependent on the presence or absence of a lysine on the extracellular end of M4 
that forms a cation-p interaction with ML3356. Only constructs bearing a lysine at position 
equivalent to K2P2.1 (TREK-1) residue 271 (K2P2.1 (TREK-1), TRAAK/EK-1 M2-C, 
TRAAK/EK-1 M3-C, and TREK-1/AAK M4-C) robustly responded to ML335 (Figure S1A-
C and G). In contrast to these results, we found no major changes with respect to the 
responses of the various chimeras to ML67-33 (Figure S1D-F and H). These findings are 
consistent with the inability of ML67-33 to discriminate between K2P2.1 (TREK-1) and 
K2P4.1 (TRAAK)26. Together, these studies show that this chimera set can identify 
selectivity determinants for activator compounds within the TREK subfamily. 
We next examined how this panel of chimeras responded to BL-1249. We found that 
the character of the donor channel with respect to BL-1249 response became 
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progressively prevalent as larger portions were swapped into the recipient channel, 
contrasting the binary changes seen for ML335 responses (Figure 4A-C, S1G, Table 1). 
Further, the patterns of changes in the BL-1249 responses were not equivalent with 
respect to the direction of the substitution. Substituting K2P4.1 (TRAAK) sequence into 
K2P2.1 (TREK-1) from the C-terminal direction caused stepwise changes in EC50 as the 
construct became dominated by the K2P4.1 (TRAAK) sequence (Figure 4A and C, 
clockwise in Figure 4A from K2P2.1 (TREK-1), EC50 = 5.5 ± 1.2, 19 ± 3, 28 ± 2, and 39 ± 9 
µM for K2P2.1 (TREK-1), TREK-1/AAK M4-C, TREK-1/AAK M3-C, and TREK-1/AAK M2-
C, respectively). By contrast, substitution of K2P4.1 (TRAAK) sequence into 
K2P2.1 (TREK-1) from the N-terminal direction caused a loss, mild recovery, and then 
further loss of BL-1249 response (Figure 4A and B, counterclockwise in Figure 4A from 
K2P2.1 (TREK-1), EC50 = 5.5 ± 1.2, 28 ± 5, 18 ± 2, 45 ± 2, and 48 ± 10 µM, for 
K2P2.1 (TREK-1), TRAAK/EK-1 M2-C, TRAAK/EK-1 M3-C, TRAAK/EK-1 M4-C, and 
K2P4.1 (TRAAK)). The complexity of the EC50 changes displayed by the chimeras with 
respect to BL-1249 contrasted with how these chimeras responded for the case in which 
there is a single site responsible for compound selectivity (Figure S1G). Such a contrast 
suggests that multiple parts of the channel make contributions that influence BL-1249 
selectivity rather than just a single site. 
K2P2.1 (TREK-1) M2 residues contribute to BL-1249 selectivity  
In the course of converting K2P2.1 (TREK-1) to K2P4.1 (TRAAK) and vice-versa by 
chimeras, the M2/M3 region stood out as a point where we found both gradual changes 
in EC50 (i.e. TREK-1/AAK M3-C à TREK-1/AAK M2-C) and stepwise changes that 
reversed the general EC50 trend (i.e. TRAAK/EK-1 M3-C à TRAAK/EK-1 M2-C).  To 
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investigate this issue further, we generated two chimeras in which only the M2 helix was 
exchanged between K2P2.1 (TREK-1) and K2P4.1 (TRAAK), TREK-1/TRAAK M2 and 
TRAAK/TREK-1 M2. The substitution of the K2P2.1 (TREK-1) M2 helix into K2P4.1 
(TRAAK) had little effect on the BL-1249 response, yielding a channel having a response 
indistinguishable from K2P4.1 (TRAAK) (EC50 = 43 ± 11 µM and 48 ± 10 µM for 
TRAAK/TREK-1 M2 and K2P4.1 (TRAAK), respectively) (Figure 5A). By contrast, the 
substitution of the K2P4.1 (TRAAK) M2 helix into K2P2.1 (TREK-1) caused a substantial 
loss in BL-1249 response (EC50 = 26 ± 8 µM and 5.5 ± 1.2 µM for TREK-1/TRAAK M2 
and K2P2.1 (TREK-1), respectively), indicating that elements from M2 contribute to the 
K2P2.1 (TREK-1) response to BL-1249. 
To identify K2P2.1 (TREK-1) M2 residues that might participate in the BL-1249 
response, we mapped the residues that differ between K2P2.1 (TREK-1) and K2P4.1 
(TRAAK) in the context of the K2P2.1 (TREK-1) structure6 (Figure 5B and C). Two K2P2.1 
(TREK-1) M2 residues stood out as candidates that could explain the reduction in BL-
1249 response when the entire M2 helix was replaced with M2 from K2P4.1 (TRAAK). 
One is at the M2/M4 interface and occurs between Phe172 and Arg297 via a p-cation 
interaction that would be lost when Phe172 is replaced with the equivalent K2P4.1 
(TRAAK) residue Met134 (Figure 5C, right inset). The second is an intrasubunit p- p 
interaction between Phe185 from M2, a site whose equivalent in K2P10.1 (TREK-2) 
Phe215 has a role in membrane stretch responses7, and Phe214 from M3 that would be 
disrupted by the replacement with the equivalent K2P4.1 (TRAAK) residue Leu147 (Figure 
5C, left inset). To assess the importance of these interactions in the context of BL-1249 
response, we made the K2P2.1 (TREK-1) mutants F172M and F185L and measured their 
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responses to BL-1249 (Figure 5D). Both changes reduced the BL-1249 response (EC50 
= 15 ± 2 µM and 27 ± 5 µM for F172M and F185L, respectively) to levels similar to the 
M2 helix swap. Notably, the M2/M3 interface substitution, F185L had a larger impact on 
the EC50, whereas the M2/M4 change F172M caused a substantial reduction in the extent 
to which the channel could be activated by BL-1249 (Figure 5D). Unlike the case for 
K2P2.1 (TREK-1), the two corresponding inverse mutations in K2P4.1 (TRAAK), M134F at 
the M2/M4 interface and L147F at the M2/M3 interface did not cause similar outcomes. 
The mutation at the M2/M4 interface had no impact on BL-1249 response (EC50, M134F 
58 ± 34 µM), whereas the change in the M2/M3 interface conferred a modest 
improvement in the BL-1249 response (EC50, L147F EC50 = 27 ± 4 µM; p < 0.001 at 35 
µM (n = 7)) (Figure 5E). Taken together, these data highlight the importance of the M2 
helix in BL-1249 activation. The observation that amino acid swaps in the M2/M3 interface 
are able to blunt the response of K2P2.1 (TREK-1) but enhance the response of K2P4.1 
(TRAAK) points to the M2/M3 interface as a key element in the differential effects of BL-
1249 on TREK subfamily members. 
The BL-1249 acidic group and tetralin are critical for potency and selectivity  
Fenamates are weak K2P modulators38, 39, 49 and their structure-activity relationships 
(SAR) with respect to K2P channels are poorly defined. Hence, we synthesized a set of 
BL-1249 derivatives in order to probe which portions of the small molecule were important 
for channel activation in the context of the differential responses of K2P2.1 (TREK-1) and 
K2P 4.1 (TRAAK). BL-1249 has two ring systems, one bearing a tetrazole and a second 
bearing a tetralin moiety. Replacement of the tetrazole by other similar functionalities 
resulted in compounds having poorer potency than BL-1249 against K2P2.1 (TREK-1) 
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(EC50 = 22±8 µM and 44±10 µM for BL-1249-amide and BL-1249-acid, respectively) 
(Figure 6A-B, Table 2). Notably, even though BL-1249-acid was slightly less potent than 
BL-1249-amide (~2-fold), it had a stronger stimulatory effect on the current than either 
BL-1249 or BL-1249-amide, suggesting that the acidic nature of the side chain is 
important for BL-1249 function (Figure 6B). Curiously, unlike what we observe for the 
TREK subfamily, for K2P 18.1 (TRESK) the change from BL-1249 to BL-1249-acid has 
been reported to switch the functional effects of the compound from an activator to an 
inhibitor49. Both BL-1249-amide and BL-1249 acid retained selectively for K2P2.1 (TREK-
1) over K2P4.1 (TRAAK) (Figures 6C-D) indicating that this moiety is not the key 
determinant of selectivity. 
To test the importance of the tetralin moiety, we synthesized a BL-1249 derivative in 
which this entity was replaced by a simple phenyl ring (BL-1249-Ph) (Figure 6A). This 
substitution proved very detrimental to activity and yielded a compound that had only a 
small amount of stimulatory effect against K2P2.1 (TREK-1) (EC50 >200µM) and showed 
a similar profile against K2P4.1 (TRAAK) revealing the importance of the bicylic tetralin 
ring for BL-1249 function (Figures 6B and E). Finally, we tested whether the conformation 
of the two aryl rings with respect to each other was important for the potency and 
selectivity of BL-1249. We made a BL-1249 derivative in which the tetralin structure was 
fused into a tricyclic scaffold to constrain the available conformations between the two 
aryl rings (BL-1249-tricycle) (Figure 6F). BL-1249-tricycle showed poorer activity against 
K2P2.1 (TREK-1) relative to BL-1249 (Figure 6G-H, EC50 = 34 ± 6 µM versus 5.5 ± 1.1 µM 
for BL-1249-tricycle and BL-1249, respectively) but, surprisingly, retained essentially the 
same activity against K2P4.1 (TRAAK) (Figure 6G-H, EC50 = 42 ± 9 µM versus 48 ± 10 
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µM for BL-1249-tricycle and BL-1249, respectively). This loss in selectivity between 
K2P2.1 (TREK-1) and K2P4.1 (TRAAK) indicates that the ability of the aryl and tetralin rings 
to adopt non-co-planar conformations is key to the preferential action of BL-1249 on 
K2P2.1 (TREK-1). We also observed that BL-1249-tricycle showed a small, but robust 
‘mode switch’ behavior versus K2P2.1 (TREK-1) manifested as inhibition between 0.1-10 
μM followed by activation at higher concentrations. This behavior was not evident against 
K2P4.1 (TRAAK) and further indicates the importance of the mobility between the two ring 
systems for the stimulatory action of BL-1249 on K2P2.1 (TREK-1). Notably, other tricyclic 
compounds have been reported to inhibit K2P2.1 (TREK-1) but not K2P4.1 (TRAAK)50 
similar to the properties of BL-1249-tricycle. Together, our studies demonstrate that both 
the acidic and tetralin moieties are important contributors to the stimulatory action of 
BL-1249 against K2P2.1 (TREK-1) and indicate that the mobility of the two aryl rings 
relative to each other is key to its selective effects on K2P2.1 (TREK-1) over K2P 4.1 
(TRAAK). 
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Discussion 
Addressing the relatively poor chemical biology surrounding the K2P family is an 
important goal that has the potential to provide tool compounds that can remove the 
current barriers to understanding how diverse inputs modulate K2P function, as well as 
the physiological roles of K2Ps in various tissues1, 24, 25. Our studies show that the fenamic 
acid derivative BL-124939, previously shown to activate K2P2.1 (TREK-1)18, 40 and 
K2P10.1 (TREK-2)7 potently and selectively activates all three members of the 
mechanosensitive TREK K2P subfamily, K2P 2.1 (TREK-1), K2P 10.1 (TREK-2) and 
K2P4.1 (TRAAK) by potentiating the potassium currents with EC50s in the low micromolar 
range when applied extracellularly. Similar to many K2P activators6, 8, 10, 26, 41, BL-1249 
enhances TREK subfamily currents by stimulating the selectivity filter C-type gate. This 
mode of action provides further evidence for the central role of this C-type gate in the 
control of K2P function. 
There are currently two structurally characterized examples for how small molecules 
can engage members of the K2P family. The co-crystal structure of K2P10.1 (TREK-2) with 
inhibitor norfluoxetine shows that this inhibitor binds in a pocket underneath the P2 helix 
of the selectivity filter at a site that is framed by the M2, M3, and M4 transmembrane 
helices and that becomes accessible when the pore lining M4 helix adopts a ‘down’ 
conformation7, 51. Although the binding site is clearly demarcated, how state-dependent 
binding of norfluoxetine inhibits is still unclear. Interestingly, besides inhibiting the 
movement of the M4 helix, the structural data indicates that the primary amine of 
norfluoxetine is near to the lower side of the selectivity filter where it could impact ion 
conduction by interfering with the electrostatic environment of the pore. The other 
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structural example shows that a pair of related molecules, ML335 and ML402, bind to a 
cryptic binding site, the K2P modulator pocket, situated behind the selectivity filter and 
sandwiched at the interface between the P1 pore helix and top of the M4 transmembrane 
helix of K2P2.1 (TREK-1)6. These activators act as wedges that stabilize the mobility of 
the P1/M4 interface, a site also impacted by gain-of-function mutations6, 10, 35, 41, and 
directly activate the C-type gate6. Understanding the extent to which other K2P 
modulators, such as BL-1249 and ML67-33, act at the norfluoxetine site, the K2P 
modulator pocket, or elsewhere on the channel is important for outlining the landscape of 
druggable sites for the K2P potassium channel class. 
Our studies of mutants and chimeras of K2P2.1 (TREK-1) and K2P4.1 (TRAAK) indicate 
that multiple channel elements that include C-terminal tail and the M2, M3, and M4 
transmembrane helices contribute to BL-1249 responses. The integrity of the C-terminal 
tail is essential for BL-1249 stimulation (Figure 3), placing BL-1249 within a diverse class 
of TREK subfamily activators that are functionally dependent on this channel element 
including lipids42, arachidonic acid45, intracellular acidosis46, chloroform45, and 
temperature41. This dependence on the C-terminal tail is notably not shared by another 
tetrazole containing small molecule activator ML67-3326. Despite the importance of the 
C-terminal tail in the BL-1249 response, our data indicate that this channel element has 
a limited role in mediating the selective action of BL-1249 on K2P2.1 (TREK-1) over K2P4.1 
(TRAAK). By contrast, we do find evidence that multiple transmembrane domains 
contribute to BL-1249 selectivity. Although in the context of K2P2.1 (TREK-1)/K2P4.1 
(TRAAK) chimeras no single transmembrane domain emerged as the predominant 
contributor, we were able to identify a site in the M2/M3 interface where exchange of a 
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single amino acid between K2P2.1 (TREK-1) and K2P4.1 (TRAAK), F185L and L147F, 
respectively, was able to shift the BL-1249 phenotype in the direction of the donor 
channel, impairing the K2P2.1 (TREK-1) response while enhancing the K2P4.1 (TRAAK) 
response. Interestingly, the M2/M3 interface is also important for TREK subfamily 
responses to temperature35 and membrane stretch52. Taken together, our findings 
suggest that BL-1249 does not act in the K2P modulator pocket but affects a site that is a 
composite of elements from multiple transmembrane helices. Although this general 
characteristic is shared with the norfluoxetine site, the role of the M2/M3 interface in BL-
1249 selectivity suggests that BL-1249 may act outside of both structurally defined small 
molecule sites. 
Our studies of a small set of BL-1249 derivatives show that the two defining moieties 
of BL-1249, the tetrazole and the tetralin groups, contribute to the stimulatory effect of 
BL-1249 TREK subfamily channels. The acidic nature at the tetrazole site and the 
hydrophobicity of the tetralin ring are both crucial for the potency of BL-1249 (Figure 6). 
Whether or not the two rings are constrained is key for the compound to discriminate 
between K2P2.1 (TREK-1) and K2P4.1 (TRAAK) as demonstrated by the properties of 
BL-1249-tricycle. This dependence on the ability of the ring systems to adopt non-
coplanar conformations in order to achieve selectivity within the TREK subfamily suggests 
that further exploration of strategies to modify the conformational preferences between 
the two ring systems might be a means to achieve better subtype discrimination. 
Interestingly, the importance of the tetrazole is a property shared by BL-1249 and 
ML67-3326 and both compounds share the general architecture of a hydrophobic ring 
system linked to the tetrazole. However, ML67-33 is not selective within the TREK 
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subfamily and rather than having hydrophobic moieties that can adopt a non-coplanar 
conformation has an acridine ring system that is constrained, not unlike BL-1249-tricycle. 
This commonality between ML67-33 and BL-1249-tricycle lends further support to the 
idea that constrained versus conformationally adaptable hydrophobic ring systems are an 
important property for the tetrazole-bearing class of TREK subfamily activators. These 
shared features suggest that further optimization of hydrophobic scaffolds bearing 
tetrazoles or other acidic groups could provide a path towards the development of other 
TREK family modulators. 
The actions of multiple diverse physical and chemical activators of the TREK 
subfamily converge at the C-type gate6, 8-10, 12, 26, 41. Our observation that BL-1249 also 
stimulates the C-type gate fits this paradigm. Our data support the idea that the BL-1249 
site of action is not in the K2P modulator pocket, the chemical modulator site closest to 
the C-type gate, but appears to reside among the transmembrane helices and supports 
the notion that changes in the channel architecture distant from the selectivity filter can 
impact the C-type gate6, 35. 
Elaboration of small molecule modulators for the TREK subfamily provides essential 
chemical biology tools for unraveling channel function and may offer new paths for 
treating issues such as pain14, 25 and arrhythmia18. Our study, together with recent 
structural work6, 7, paints a complex landscape in which there are multiple points for small 
molecules to intervene in K2P function. Given the growing and diverse list of small 
molecules that influence various K2Ps14, 26-28, 36, 50, 53-57, further definition of the types of 
sites with which small molecules can bind and impact K2P function through combined 
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efforts of structural, functional, and computational studies will be crucial for defining how 
precise chemical control of K2P activity can be achieved. 
  
  49 
 
Materials and Methods 
Molecular Biology 
Constructs for murine K2Ps, including: K2P2.1 (TREK-1) (Gene ID: 16526), 
K2P10.1 (TREK-2) (Gene ID: 72258), K2P4.1 (TRAAK) (Gene ID: 16528), K2P5.1 (TASK-
2) (Gene ID: 16529), K2P3.1 (TASK-1) (Gene ID: 16527), K2P9.1 (TASK-3) (Gene ID: 
223604), K2P18.1 (TRESK) (Gene ID: 332396) in pGEMHE/pMO were used for Xenopus 
oocyte experiments as previously described10, 26. Murine K2P2.1 (TREK-1) (Gene ID: 
16526) was expressed in HEK-293 cells using a pIRES-EGFP construct as previously 
described26. Murine K2P13.1 (THIK-1) (Gene ID: 217826) and K2P1.1 (TWIK-1) (Gene ID: 
16525) were cloned into pGEMHE/pMO for use in Xenopus oocytes. Chimeras were 
designed using EMBOSS Needle pairwise sequence alignment tool58 to match 
homologous helices in K2P2.1 (TREK-1) and K2P4.1 (TRAAK) and were assembled using 
the Gibson assembly method59. Chimera boundaries are Thr152, TREK-1/AAK M2-C; 
Trp199, TREK-1/AAK M3-C; and Y272, TREK-1/AAK M4-C, Thr114, TRAAK/EK-1 M2-
C; Trp161, TRAAK/EK-1 M3-C; and Tyr234 K2P4.1 (TRAAK). All sequences were verified 
using DNA sequencing. 
Patch clamp electrophysiology 
Mouse K2P2.1 was expressed from a previously described pIRES2-EGFP vector in 
HEK293T cells (ATCC CRL-1573TM). 70% confluent cells were transfected (in 35-mm 
diameter wells) with LipofectAMINE 2000 (Invitrogen) for 6 h, and plated onto coverslips 
coated with Matrigel (BD Biosciences). 
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Voltage-dependent activation of K2P2.1 was recorded on excised patches in inside-
out configuration (50 kHz sampling) in the absence and presence of 1 μM BL-1249. 
Pipette solution contained the following: 150 mM KCl, 3.6 mM CaCl2, 10 mM HEPES (pH 
7.4 with KOH). Bath solution contained the following: 150 mM RbCl, 2 mM EGTA and 
10 mM HEPES (pH 7.4 with RbOH), and was continuously perfused at 200 ml per hour 
during the experiment. TREK-1 currents were elicited by a 10 mV voltage step protocol 
from −100 mV to +100 mV, from a -80 mV holding potential. Data were analysed using 
Clampfit 9 and Origin 7. 
Two-electrode voltage-clamp (TEVC) electrophysiology 
Xenopus laevis oocytes were harvested in accordance with UCSF IACUC protocol 
AN129690 and digested in calcium-free ND-96 (96 mM NaCl, 2 mM KCl, 3.8 mM MgCl2) 
immediately following harvest, as previously described6, 10. Digested oocytes were 
maintained in standard ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, 10 
mM HEPES, pH 7.4) with antibiotics (100 units ml-1 Penicillin, 100 μg ml-1 Streptomycin, 
50 μg ml-1Gentimycin). Defolliculated stage V-VI oocytes were injected with 0.2-6.0 ng of 
mRNA in 50 nL and currents were recorded 24-48 hours after injection. mRNA was 
synthesized from plasmid DNA using mMessage mMachine Kit (T7 promoter, Ambion, 
Life Technologies) and purified using RNEasy Kit (Qiagen). Injected oocytes were 
impaled with two standard microelectrodes (0.2 – 1.0 MΩ) filled with 3M KCl and 
subjected to constant profusion of standard ND96 during recording. Currents were 
amplified using the GeneClamp 500B (MDS Analytical Technologies) amplifier controlled 
by the pClamp software (Molecular Devices). Data were digitized at 1 kHz using Digidata 
1332A (MDS Analytical Technologies). For all experiments with small molecules, basal 
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currents were evoked using 1s long ramps from -150 to +50 mV under constant profusion 
of ND96. Once stabilized basal currents were recorded, compounds were perfused at 
various concentrations in standard ND96 and currents were allowed to increase to 
stabilization before recording final current. Fold activation upon compound application is 
expressed as I/I0 (0 mV), derived from the current at 0 mV in presence of compound 
divided by the basal current at 0 mV in standard ND96 without compound. Data were 
analyzed and plotted using Graphpad Prism Version 5 (GraphPad Software, San Diego 
California USA, www.graphpad.com). In cases where saturation could not be reached 
due to BL-1249 solubility limits, EC50 was estimated using an upper bound of I/I0 was set 
to 15 for the fits. In the case of BL-1249-acid EC50 estimation, upper bound of I/I0 was set 
to 20 to account for the strong stimulation of BL-1249-acid. 
BL-1249 analogue chemical synthesis 
Complete methods for the synthesis of BL-1249 analogs, BL-1249-acid, BL-1249-
amide, BL-1249-Ph, and BL-1249-tricycle are found in the supplementary material and 
are available online. 
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Figure 2.1 | External application of BL-1249 selectively activates 
mechanosensitive K2Ps 
 
A, Exemplar current traces for specified K2Ps (black) with 10 µM BL-1249 (light blue) as 
measured via TEVC in Xenopus oocytes. B, K2P channel phylogenetic tree. Stars denote 
assayed representative K2Ps. Blue stars indicate BL-1249 responsive channels. C, BL-
1249 dose-response curves for K2P2.1(TREK-1) (blue circles), K2P10.1(TREK-2) (black 
triangles), and K2P4.1(TRAAK) (orange squares). (EC50 = 5.5 ± 1.2 μM, 8.0 ± 0.8 μM and 
48 ± 10 μM, respectively. D, BL-1249 responses of indicated K2Ps. Inset shows expanded 
view of poorly responsive K2Ps. Error bars are s.e.m. 
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Figure 2.2 | BL-1249 activates the K2P2.1 (TREK-1) C-type gate 
A, and B, Exemplar current traces for A, K2P2.1 (TREK-1) and B, K2P2.1 (TREK-1) with 
1µM BL-1249 in HEK293 inside-out patches in 150 mM K+[out]/150 mM Rb+[in]. Inset shows 
voltage protocol. C, and D, Current-voltage relationships for C, K2P2.1 (TREK-1) and D, 
K2P2.1 (TREK-1) with 1µM BL-1249. E, Rectification coefficients (I+100mV/I-100 mV) from 
recordings (n ≥ 3) made in (‘A’-‘D’). F, Dose-response curves in Xenopus oocytes for 
K2P2.1 (TREK-1) (blue circles), K2P2.1(TREK-1) G137I (purple squares), and 
K2P2.1(TREK-1) W275S (orange triangles) K2P2.1(TREK-1): 5.5 ± 1.2 μM, G137I and 
W275S >60 μM. K2P2.1(TREK-1) data are from Figure 1C. Error bars are s.e.m.. 
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Figure 2.3 | K2P2.1(TREK 1) C-terminus affects BL-1249 response 
A, Exemplar current traces for K2P2.1(TREK-1)GGG (black) with 20 µM BL-1249 (green) 
and BL-1249 dose-response curves for K2P2.1(TREK-1) (blue circles) and 
K2P2.1(TREK-1)GGG (green circles) (EC50 = 5.5 ± 1.2 μM and 19 ± 1 μM, respectively). 
Green star in cartoon indicates site of GGG mutation. B, Exemplar current traces for 
K2P2.1(TREK-1) D322 (magenta) and K2P2.1(TREK-1) D308 (purple) with 20 µM BL-1249 and 
BL-1249 dose-response curves for K2P2.1(TREK-1) (blue circles), K2P2.1(TREK-1) D322 
(purple squares), and K2P2.1(TREK-1) D308 (magenta triangles). (EC50 = 5.5 ± 1.2 μM, 
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26 ± 8 μM, and 35 ± 8 μM, respectively). Magenta and purple lines in cartoon indicates 
site of D322 and D308 truncations, respectively. C, Exemplar current traces for TREK-
1/AAK_T (black) and with 20 µM BL-1249 (cyan). BL-1249 dose-response curves for 
K2P2.1(TREK-1) (blue circles), K2P4.1(TRAAK) (light orange squares), and 
TRAAK/EK1_T (light blue triangles). (EC50 = 5.5 ± 1.2 μM, 48 ± 10 μM, and 7.7 ± 0.6 μM, 
respectively). Cartoon indicates TREK-1/AAK_T channel regions from K2P2.1 (blue) and 
K2P4.1 (yellow). D, Exemplar current traces for TRAAK/EK_T (black) and with 20 µM BL-
1249 (orange). BL-1249 dose-response curves for K2P2.1(TREK-1) (blue circles), 
K2P4.1(TRAAK) (light orange squares), and TRAAK/EK_T (orange triangles) (EC50 = 
5.5 ± 1.2 μM, 48 ± 10 μM, and 23 ± 4 μM, respectively). Cartoon indicates TRAAK/EK_T 
channel regions from K2P2.1 (blue) and K2P4.1 (light orange). In A-D, K2P2.1(TREK-1) and 
K2P4.1(TRAAK) data are from Figure 1C. Error bars are s.e.m. 
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Figure 2.4 | BL-1249 responses of TREK-1/TRAAK chimeras 
A, Exemplar current traces for of BL-1249 responses for K2P2.1(TREK-1) (blue), 
K2P4.1(TRAAK) (light orange), and chimeras TREK-1/AAK M4-C (light blue), 
TREK-1/AAK M3-C (green), TREK-1/AAK M2-C (light green), TRAAK/EK-1 M4-C (light 
green), TRAAK/EK-1 M3-C (green), TRAAK/EK-1 M2-C (light blue) Black and colored 
traces show basal and currents with 20 μM BL-1249, respectively. Cartoon schematics 
show channel portions from K2P2.1(TREK-1) (blue) and K2P4.1(TRAAK) (light orange). B, 
and C, Dose-response curves for K2P2.1(TREK-1), K2P4.1(TRAAK) and the indicated 
chimeras. (EC50 = 5.5 ± 1.2 μM, 48 ± 10 μM, 19 ± 3 μM, 28 ± 3 μM, 39 ± 9 μM, 45 ± 2 
μM, 18 ± 2 μM, 28 ± 5 μM, for K2P2.1(TREK-1), K2P4.1(TRAAK), TREK-1/AAK M4-C, 
TREK-1/AAK M3-C, TREK-1/AAK M2-C, TRAAK/EK1 M4-C, and TRAAK/EK1 M3-C, 
TRAAK/EK1 M2-C, respectively). K2P2.1(TREK-1) and K2P4.1(TRAAK) data are from 
Figure 1C. Error bars are s.e.m.. 
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Figure 2.5 | M2 residues contribute to BL-1249 selectivity between K2P2.1 (TREK 1) 
and K2P4.1 (TRAAK) 
A, Exemplar current traces for TREK-1/TRAAK M2 (light blue) and TRAAK/TREK-1 M2 
(orange) with 20 µM BL-1249 (left). Insets depict M2 helix swap. BL-1249 dose-response 
curves (right) for K2P2.1 (TREK-1) (blue circles), TREK-1/TRAAK M2 (light blue squares), 
K2P4.1(TRAAK) (light orange circles) and TRAAK/TREK-1 M2 (orange triangles). 
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(EC50 = 5.5 ± 1.2 μM, 26 ± 8 μM, 48 ± 10 μM and 43 ± 11 μM, respectively). B, Alignment 
of K2P2.1 (TREK-1) and K2P4.1 (TRAAK) M2 sequences. Non-conserved residues are 
highlighted in yellow. C, K2P2.1(TREK-1) (PDB 6CQ6)6 structure. Residues that differ 
from K2P4.1 (TRAAK) are highlighted yellow. Panel insets show the environment 
surrounding the highlighted M2 residues. D, Exemplar current traces for TREK-1/F172M 
(pink) and TREK-1/F185L (light blue) with 20 µM BL-1249. BL-1249 dose-response 
curves for K2P2.1(TREK-1) (blue circles), TREK-1/F172M (pink circles), K2P2.1 (F185L) 
(light blue squares) and K2P4.1(TRAAK) (light orange circles). (EC50 = 5.5±1.2 μM, 15±2 
μM, 27±5 μM and 48 ± 10 μM, respectively). E, Exemplar current traces for 
TRAAK/M134F (orange triangles) and TRAAK/L147F (olive green squares) with 20 µM 
BL-1249. BL-1249 dose-response curves for K2P2.1 (TREK-1) (blue circles), 
TRAAK/M134F (orange triangles), TRAAK/L147F (olive green squares) and 
K2P4.1(TRAAK) (light orange circles). (EC50 = 5.5 ± 1.2 μM, 58 ± 34 μM, 27 ± 4 μM and 
48 ± 10 μM, respectively). K2P2.1(TREK-1) and K2P4.1(TRAAK) data are from Figure 1C. 
Inset compares responses at 35 µM BL-1249. *** indicates p < 0.001 for a one-way 
ANOVA test. ‘n.s.’ no significant difference. Error bars are s.e.m. 
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Figure 2.6 | Structure activity relationships of BL-1249 analogues 
A, Chemical structures of BL-1249 and analogues. ‘I’ and ‘II’ indicates the substitution 
sites. B, Dose-response of K2P2.1 (TREK-1) for BL-1249 (black) (from Figure 1C), BL-
1249-amide (blue), BL-1249-acid (light blue) and BL-1249-Ph (red) (EC50= 5.5 ± 1.2 μM, 
22 ± 8 μM, 44 ± 10 μM and >100 μM, respectively). K2P2.1(TREK-1) and K2P4.1(TRAAK) 
data are from Figure 1C. C-E, Exemplar current traces for K2P2.1 (TREK-1) with 25 µM 
BL-1249-amide (blue), BL-1249-acid (light blue) and BL-1249-Ph (red), respectively (top), 
chemical structures of BL-1249 analogues (middle), and dose response of K2P2.1 
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(TREK-1) (blue) and K2P4.1(TRAAK) (light orange) (bottom). F, Chemical structure of 
BL-1249-tricycle. G, Exemplar current traces for K2P2.1 (TREK-1) and K2P4.1 (TRAAK) 
with 25 µM BL-1249-tricycle (purple). H, Dose-response of K2P2.1 (TREK-1) (blue) and 
K2P4.1 (TRAAK) (light orange) for BL-1249-tricycle (EC50= 34 ± 6 μM and 42 ± 9 μM, 
respectively). Error bars are s.e.m. 
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Figure 2.7 | Supplementary Figure 1 - Responses of TREK-1/TRAAK chimeras to 
ML355 and ML67-33 activators. 
A, ML335 chemical structure. B, and C, ML335 dose-response curves for: TREK-1/AAK 
M4-C (light blue), TREK-1/AAK M3-C (green), and TREK-1/AAK M2-C (light green) 
(EC50 =  .0 ± 0.6 μM, >100 μM, and >100 μM, respectively), and TRAAK/EK-1 M4-C (light 
green), TRAAK/EK-1 M3-C (green), and TRAAK/EK-1 M2-C (light blue) (EC50 = >100 μM, 
13 ± 2 μM, and 8 ± 1 μM respectively). D, ML67-33 chemical structure. E, and F, ML67-
33 dose-response curves for: TREK-1/AAK M4-C (light blue), TREK-1/AAK M3-C (green), 
and TREK-1/AAK M2-C (light green), (EC50 = 42 ± 3 μM, 49 ± 22 μM, and 42 ± 3 μM, 
respectively), and TRAAK/EK-1 M4-C (light green), TRAAK/EK-1 M3-C (green), 
TRAAK/EK-1 M2-C (light blue), (EC50 = 31 ± 3 μM, 44 ± 14 μM,, and 33 ± 1 μM, 
respectively). G and H, Spider plot of EC50s for the indicated chimeras. Cartoon 
  73 
 
schematics show channel portions from K2P2.1(TREK-1) (blue) and K2P4.1(TRAAK) (light 
orange). Error bars are s.e.m. 
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Figure 2.8 | Supplementary Figure 2 - Exemplar responses of TREK-1/TRAAK 
chimeras to ML355 and ML67-33 activators 
A, Chemical structure of ML335 and exemplars for responses of TREK-1/AAK M4-C (light 
blue), TREK-1/AAK M3-C (green), TREK-1/AAK M2-C (light green), TRAAK/EK-1 M4-C 
(light green), TRAAK/EK-1 M3-C (green), and TRAAK/EK-1 M2-C (light blue) to 50 µM 
ML335. B, Chemical structure of ML67-33 and exemplars for responses to 50 µM ML67-
33. Colors are as in ‘A’. 
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Table 2.1 | Summary of K2P response to BL-1249 
Background Mutant EC50 (µM) n (≥) 
 
 
 
 
K2P2.1 (TREK-1) 
 
- 5.5 ± 1.2 3 
K2P2.1 (TREK-1)GGG 19 ± 1 3 
K2P2.1 (TREK-1)Δ322 26 ± 8* 2 
K2P2.1 (TREK-1)Δ308 35 ± 8* 2 
TREK-1/AAK_T 7.7 ± 0.6 2 
TREK-1/AAK M4-C 19 ± 3 3 
TREK-1/AAK M3-C 28 ± 2 3 
TREK-1/AAK M2-C  39 ± 9 3 
TREK-1/TRAAK M2 26 ± 8 3 
F172M 15 ± 2 3 
F185L 27 ± 5 3 
K2P10.1 
(TREK-2) 
- 8.0 ± 0.8 3 
K2P4.1 (TRAAK) 
 
- 48 ± 10* 3 
TRAAK/EK1_T 23 ± 4 2 
TRAAK/EK1 M4-C 45 ± 2 3 
TRAAK/EK1 M3-C  18 ± 2 3 
TRAAK/EK1 M2-C  28 ± 5 3 
TRAAK/TREK-1 M2 43 ± 11 3 
M134F 58 ± 34* 2 
L147F 27 ± 4 3 
*Denotes experiments where complete saturation of the response could not be reached 
due to BL-1249 solubility limits. For these cases, fits were imposed with an upper 
boundary of 15 (Fold Activation, I/I0) to estimate EC50 and error. 
 
Data derived from at least two independent experiments with each data point averaged 
from at least three oocytes 
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Table 2.2 | Summary of BL-1249 analogue activation of K2P2.1 (TREK-1) and 
K2P4.1 (TRAAK) 
Compound K2P2.1 (TREK-1) 
EC50 (µM) 
n (≥) K2P4.1 (TRAAK) 
EC50 (µM) 
n (≥) 
 -    
BL-1249 5.5 ± 1.2 3 48 ± 10* 3 
BL-1249 amide 22 ± 8 3 >200 3 
BL-1249-acid 44 ± 10** 4 >200 2 
BL-1249-Ph >200 3 >200 3 
BL-1249-tricycle 34 ± 6  2 42 ± 9 3 
     
 
* EC50 estimated imposing with an upper boundary of 15 (Fold Activation, I/I0) 
** EC50 estimated imposing with an upper boundary of 20 (Fold Activation, I/I0) 
 
Data derived from at least two independent experiments with each data point averaged 
from at least three oocytes 
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Chapter 3 : Polynuclear ruthenium amines inhibit K2Ps via a ‘finger in the dam’ 
mechanism 
Lianne Pope, Marco Lolicato and Daniel L. Minor, Jr. 
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Abstract 
The trinuclear ruthenium amine Ruthenium Red (RuR) inhibits diverse ion channels 
including K2P potassium channels, TRPs, the mitochondrial calcium uniporter, CALHMs, 
ryanodine receptors, and Piezos. Despite this extraordinary array, there is very limited 
information for how RuR engages its targets. Here, using X-ray crystallographic and 
electrophysiological studies of an RuR-sensitive K2P, K2P2.1 (TREK-1) I110D, we show 
that RuR acts by binding an acidic residue pair comprising the ‘Keystone inhibitor site’ 
under the K2P CAP domain archway above the channel pore. We further establish that 
Ru360, a dinuclear ruthenium amine not known to affect K2Ps, inhibits RuR-sensitive K2Ps 
using the same mechanism. Structural knowledge enabled a generalizable RuR 
‘super-responder’ design strategy for creating K2Ps having nanomolar sensitivity. 
Together, the data define a ‘finger in the dam’ inhibition mechanism acting at a novel K2P 
inhibitor binding site. These findings highlight the polysite nature of K2P pharmacology and 
provide a new framework for K2P inhibitor development. 
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Introduction 
Ruthenium red (RuR)1 (Figure 1A) is a trinuclear oxo-bridged ruthenium amine 
polycation with many biological applications2, including a ~50 year legacy of use as an 
inhibitor of diverse ion channels, such as select members of the K2P (KCNK) family3-6, 
numerous TRP channels7-14, the mitochondrial calcium uniporter (MCU)15-18, CALHM 
calcium channels19-21, ryanodine receptors 22, 23, and Piezo channels24, 25. Despite this 
remarkably wide range of ion channel targets and the recent boom in ion channel 
structural biology, structural understanding of how RuR acts on any ion channel is limited 
to a recent cryo-EM study of the CALHM2 channel that provides few molecular details 
regarding the coordination chemistry that underlies RuR binding21. In the case of K2Ps, 
functional studies have established that a negatively charged residue at the base of the 
K2P extracellular domain that forms an archway over the channel pore, the CAP domain, 
comprises a key RuR sensitivity determinant in the natively RuR sensitive channels 
K2P9.1 (TASK-3)4-6 and K2P10.1 (TREK-2)3. Further, installation of a negatively charged 
amino acid at the equivalent CAP domain site in a non-RuR sensitive channel is sufficient 
to confer RuR sensitivity3. The archway above the selectivity filter extracellular mouth 
made by the K2P CAP domain creates a pair of water-filled portals, the extracellular ion 
pathway (EIP), through which ions exit the channel under physiological conditions26-29. 
Although the EIP has been proposed as the site of RuR action3,6, the mechanism by which 
RuR inhibits K2Ps remains unresolved and to date there is no direct structural evidence 
indicating that the EIP can be targeted by RuR or any other class of small molecule or 
protein-based inhibitors. 
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K2Ps produce an outward ‘leak’ potassium current that plays a critical role in stabilizing 
the resting membrane potential of diverse cell types in the nervous, cardiovascular, and 
immune systems30-32. There are fifteen K2P subtypes comprising six subfamilies in which 
the channel monomers assemble into dimers wherein each subunit contributes two 
conserved pore forming domains to make the channel pore26-29,31,33. A range of physical 
and chemical signals control K2P function30-32 and various K2P subtypes have emerging 
roles in a multitude of physiological responses and pathological conditions such as action 
potential propagation in myelinated axons34,35, anesthetic responses36,37, microglial 
surveillance38, sleep duration39, pain40-42, arrythmia43, ischemia36,44,45, cardiac fibrosis46, 
depression47, migraine48, intraocular pressure regulation49, and pulmonary 
hypertension50. Although there have been recent advances in identifying new K2P 
modulators28,42,51-55 and in defining key structural aspects of K2P channel 
pharmacology27,28,56, as is the case with many ion channel classes, pharmacological 
agents targeting K2Ps remain poorly developed and limit the ability to probe K2P 
mechanism and biological functions57. 
Here, we present X-ray crystal structures of a K2P2.1 (TREK-1) mutant bearing a single 
change at the site that controls K2P channel RuR sensitivity, K2P2.1 I110D, alone and 
complexed with two different polynuclear ruthenium amines, RuR and the dinuclear 
ruthenium amine, Ru36058, an inhibitor of the mitochondrial calcium uniporter15,59,60 not 
previously known to affect potassium channels. The structures show that the negatively 
charged residues at position 110 comprise ‘the Keystone inhibitor site’ on the ceiling of 
the CAP archway to which positively charged RuR and Ru360 bind through ionic 
interactions. This interaction holds the polybasic compounds directly over the mouth of 
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the channel pore, blocks one EIP arm, and prevents channel function. Functional studies 
corroborated by a crystal structure of K2P2.s I110D bound simultaneously to RuR and a 
small molecule activator of the channel selectivity filter ‘C-type gate’, ML33528, establish 
that polynuclear ruthenium amine inhibition of K2Ps is unaffected by C-type gate 
activation. Using molecular recognition principles derived from the structures of the 
K2P:RuR and K2P:Ru360 complexes, we demonstrate a general design strategy for 
endowing any K2P channel with nanomolar RuR sensitivity. Our work establishes that 
polynuclear ruthenium compounds act through a ‘finger in the dam’ mechanism to inhibit 
K2P function by binding under the CAP domain archway at the Keystone inhibitor site and 
blocking the pore. The structural definition of this new modulatory site demonstrates the 
importance of electronegativity and specific sidechain geometry for polynunclear amine 
molecular recognition, defines a new small molecule binding site that augments the rich, 
polysite pharmacology of K2P modulation, and opens a path for targeting the Keystone 
inhibitor site and EIP for the development of new K2P modulators. 
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Results 
A single site in the K2P CAP domain confers RuR sensitivity 
K2P2.1 (TREK-1) is the founding member of the thermo- and mechanosensitive 
subgroup of K2Ps31,61. Although this channel is resistant to RuR inhibition (Figure 1B and 
D, Table 1)3, two electrode voltage clamp (TEVC) recordings in Xenopus oocytes of 
outward current inhibition by RuR under physiological ionic conditions showed that 
installation of a point mutation I110D at the base of the K2P2.1 (TREK-1) CAP domain 
conferred sub-micromolar RuR sensitivity to K2P2.1 (TREK-1) (IC50 = 0.287 ± 
0.054 µM)(Figures. 1C-D, Table 1). This inhibition followed a 1:1 RuR:channel 
stoichiometry, in agreement with K2P studies using other recording protocols3,5, and 
validates previous studies showing that this point mutant renders K2P2.1 (TREK-1) 
sensitive to RuR3. Importantly, the response of K2P2.1 I110D to RuR matched that of the 
closely-related, natively-RuR sensitive K2P10.1 (TREK-2)3 in which there are native 
aspartate residues at the K2P2.1 Ile110 analogous site (Figures 1D and S1A, Table 1) 
(IC50 = 0.287 ± 0.054 and 0.23 ± 0.06 µM for K2P2.1 I110D and K2P10.1 (TREK-2)3, 
respectively), suggesting that the I110D change to K2P2.1 (TREK-1) captures the essence 
of the requirements for RuR inhibition. 
Because another natively-RuR sensitive K2P, K2P9.1 (TASK-3), has a glutamate at the 
K2P2.1 I110D equivalent site (Figure S1A) that is essential for its RuR response4-6, we 
asked whether I110E would also render K2P2.1 (TREK-1) sensitive to RuR. Indeed, TEVC 
measurements showed that RuR inhibited K2P2.1 I110E (IC50 =13.6 ± 2.7 µM, Table 1) 
(Figures 1D and S1B, Table 1). RuR inhibition was ~50 fold weaker than that observed 
for K2P2.1 I110D, indicating that the I110D and I110E changes are not equivalent even 
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though both bear similar negative charges. Further, introduction of a positively charged 
residue, K2P2.1 I110K, yielded channels as insensitive to RuR as K2P2.1 (TREK-1) 
(Figures 1D and S1C). RuR inhibition was essentially independent of voltage for K2P2.1 
I110D and K2P2.1 I110E (Figures S1D-G), consistent with prior reports of RuR inhibition 
of other K2Ps62. Together, these results provide key support for the idea that a negative 
charge at the K2P CAP domain base is a crucial determinant of RuR inhibition of K2Ps3-6. 
Importantly, the observation of the ~50 fold difference between the RuR sensitivity of two 
essentially equivalently negatively charged residues in the same structural context, 
K2P2.1 I110D and K2P2.1 I110E (Figure 1D, Table 1) indicates that electrostatics is not 
the sole factor contributing to the RuR:channel interaction and points to a role for the 
detailed geometry of the interaction of the negatively charged residues with RuR. 
Structural definition of the K2P RuR binding site 
To understand how RuR inhibits K2P channels, we determined the X-ray crystal 
structures of K2P2.1 I110D alone and bound to RuR at resolutions of 3.40Å and 3.49Å, 
respectively (Table S1) on the background of the previously crystallized construct K2P2.1 
(TREK-1)cryst28. Apart from the I110D change, the overall structure of K2P2.1 I110D was 
essentially identical to K2P2.1 (TREK-1)cryst (RMSDCa = 0.575Å). Importantly, K2P2.1 
I110D was structurally similar to the natively-RuR sensitive K2P10.1 (TREK-2)28 
(RMSDCa= 0.938Å), especially in the neighborhood of K2P10.1 (TREK-2) Asp140 (Figure 
S2A, Table S2), the residue that is fundamental to K2P10.1 (TREK-2) RuR sensitivity3. 
Hence, when taken together with the functional similarity to K2P10.1 (TREK-2), the K2P2.1 
I110D:RuR complex should capture the essential elements that contribute to the RuR 
response of natively RuR-sensitive K2Ps. 
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The K2P2.1 I110D:RuR complex structure shows that RuR binds under the CAP 
domain archway directly above the selectivity filter at a site we term the ‘Keystone inhibitor 
site’ due to the location of the I110D residues at the peak of the CAP archway ceiling 
(Figures 1E and S2B-C). RuR binds with  a 1:1 stoichiometry to the channel that matches 
expectations from functional studies (Table 1)3,5,62. To facilitate description of this and 
other RuR complexes, we designate the three RuR ruthenium amine centers as RuA, RuB, 
and RuC. RuR binds at ~45° angle relative to the CAP and selectivity filter in a pose that 
places one of the terminal ruthenium-amine moieties, RuA, directly above the column of 
selectivity filter ions in a position that overlaps with the S0 ion site from the K2P2.1 I110D 
structure (Figures 1F and S2B). The RuB and RuC moieties block one EIP arm (Figures 
1E-F). Notably, the observed pose is very different from the previously proposed 
horizontal RuR binding pose in which the RuB moiety sits above the column of selectivity 
filter ions6. The I110D carboxylates coordinate RuR directly through electrostatic 
interactions with all three ruthenium-amine moieties using a multipronged set of 
interactions (Figure 1F and G). Such direct coordination suggests why K2P2.1 I110D and 
K2P2.1 I110E have different magnitude RuR responses, as the extra methylene groups in 
K2P2.1 I110E would not allow the same type of direct coordination observed for the 
smaller aspartate pair (Figure 1G). Besides direct electrostatic interactions, there are van 
der Waals contacts between RuC and the side chain of CAP residue Val107 from chain 
A, RuA and RuB with Asn111 from each chain of the dimer, RuA with Asp256 from chain 
B, and RuB with Gly255 from chain B. Apart from a slight reorientation of the I110D 
sidechains and CAP to accommodate RuR (Figure S2D), there are only minor 
conformational changes with respect to the unbound K2P2.1 I110D 
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(RMSDCa=  0.688Å)(Table S2). Hence, RuR binds to an essentially pre-organized 
electronegative binding site at the CAP base. 
K2P RuR binding is independent of C-type gate activation 
Activation of the selectivity filter, ‘C-type’ gate is central to K2P function28,63-66. Because 
RuR binds directly above the selectivity filter and overlaps with the S0 ion, we asked 
whether C-type gate activation by mutation, G137I63,67 or by a small molecule activator, 
ML33528, would impact RuR inhibition of K2P2.1 I110D (Figure 2A-B). TEVC experiments 
showed that RuR inhibits K2P2.1 I110D/G137I with an IC50 (IC50 = 0.154 ± 0.023 µM) that 
is very similar to that for K2P2. I110D, indicating that C-type gate activation does not 
influence RuR block of the channel (Figure 2C, Table 1). 
Before assessing whether RuR inhibition was influenced by ML335 activation, we first 
measured the activation of K2P2.1 I110D by ML335. The I110D change is >15Å from the 
K2P modulator pocket that forms the ML335 binding site and is not expected to impact 
ML335 activation. In line with these expectations, there was no difference in the response 
of K2P2.1 I110D to ML335 activation relative to K2P2.1 (TREK-1) (EC50 (ML335) = 11.8 ± 2.3 
and 14.3 ± 2.7 µM for K2P2. I110D and K2P2.1 (TREK-1)28, respectively) (Figures S3A-B). 
Importantly, similar to the observations with the G137I C-type gate activation mutant, 
pharmacological C-type gate activation by saturating amounts of ML335 had minimal 
impact on the RuR response relative to K2P2.1 I110D (IC50 = 0.173 ± 0.021 µM, Table 1). 
Together, these data demonstrate that RuR inhibition is essentially independent of C-type 
gate activation (Figures 2A-D, Table 1) and are consistent with the observed position of 
RuR above the selectivity filter. 
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To see whether there might be structural differences in the interaction of RuR with an 
activated C-type gate, we determined the structure of the K2P2.1 I110D:RuR:ML335 
complex at 3.00Å resolution (Figures 2E and S3C-D, Table S1). This structure is very 
similar to the K2P2.1 I110D:RuR complex (Figures S3C-E) (RMSDCa = 0.507Å) and to the 
previously determined K2P2.1:ML335 complex28 (RMSDCa = 0.480Å) (Table S2). The 
structure shows that RuR binds to the Keystone inhibitor site using a pose that is very 
similar to that in the K2P2.1 I110D:RuR complex. Both I110D sidechains coordinate 
multiple Ru centers though direct interactions to RuR (Figures 2F-G) like those in the 
K2P2.1 I110D:RuR complex and there are van der Waals contacts with residues in the 
CAP and selectivity filter outer mouth. These fundamental similarities in binding to the 
Keystone inhibitor site are consistent with the similar IC50s measured with or without 
ML335 C-type gate activation (Figures 2C-D,Table 1). 
Polynuclear ruthenium compounds inhibit K2Ps at a common site 
The dinuclear oxo-bridged ruthenium compound, Ru360 (Figure 3A)58, has many 
characteristics in common with RuR (cf. Figure 1A). Ru360 is best known as an inhibitor 
of the mitochondrial calcium uniporter (MCU) 15,59,60, a property it shares with RuR68. Yet, 
despite its structural similarity to RuR and the fact that both Ru360 and RuR inhibit MCU, 
Ru360 has not been reported to block K2P channels. To ask whether Ru360 might inhibit 
RuR-sensitive K2P channels, we used TEVC to measure the Ru360 responses of 
K2P2.1 (TREK-1), K2P2.1 I110D, and the natively RuR sensitive K2Ps, K2P10.1 (TREK-2)3 
and K2P9.1 (TASK-3)4-6. Application of 100 µM Ru360 to K2P2.1 (TREK-1) had no effect, 
consistent with the insensitivity of this channel to RuR (Figures 3B and F). However, in 
stark contrast, Ru360 inhibited all of the RuR sensitive K2Ps with micromolar potency (IC50 
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= 11.3 ± 1.8, 2.8 ± 1.2, and 15.6 ± 2.7 µM for K2P2.1 I110D, K2P10.1 (TREK-2), and 
K2P9.1 (TASK-3), respectively) (Figures 3C-F, Table 1). Similar to RuR inhibition, Ru360 
block of K2Ps was independent of voltage (Figures S4A-D). For both K2P2.1 I110D and 
K2P10.1 (TREK-2) the Ru360 IC50s are >10-fold weaker than those for RuR. Because 
there is a reported 30-fold discrepancy in the IC50 of RuR for K2P9.1 (TASK-3) in the 
literature (0.35 µM5 vs.10 µM6) that precluded a direct comparison with our Ru360 data, 
we measured inhibition of K2P9.1 (TASK-3) by RuR to resolve whether RuR and Ru360 
had similar or different IC50s for K2P9.1 (TASK-3). Our TEVC experiments measured a 
sub-micromolar IC50 for RuR inhibition of K2P9.1 (TASK-3) (IC50 = 0.114 ± 0.021 µM) 
(Figures S4E-F, Table 1) that agrees with other Xenopus oocyte TEVC studies5. These 
data establish that, as with the other polynuclear ruthenium-sensitive K2Ps we studied, 
Ru360 is a weaker inhibitor of K2P9.1 (TASK-3) than RuR. The uniformly weaker potency 
of Ru360 versus RuR against K2Ps correlates with the fact that Ru360 carries half the 
positive charge of RuR (+3 versus +6) and underscores the important role that 
electrostatics plays in the binding of these polycations. 
To understand the details of how Ru360 inhibits K2Ps, we determined of a 3.51Å 
resolution X-ray crystal structure of the K2P2.1 I110D:Ru360 complex (Figures 3G-H, 
Table S1). As with the RuR complexes, the K2P2.1 I110D:Ru360 complex has a channel 
structure that is overall very similar to the structure of the K2P2.1 I110D in the absence of 
the inhibitor (RMSDCa = 0.665Å) and to the K2P2.1 I110D:RuR complex (RMSDCa = 
0.561Å) (Figure S4G, Table S2). Ru360 binds to the Keystone inhibitor site in a pose that 
matches RuR (Figures 3H and S4G-I). Notably, even though Ru360 has one fewer 
ruthenium atoms than RuR, one of the Ru360 ruthenium-amine moieties, denoted RuA, 
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occupies essentially the same site as the RuR RuA moiety and overlaps with the S0 ion 
site (Figure 3H), while the other ruthenium amine, RuB, overlaps the position of the RuR 
RuB moiety and blocks one EIP arm. There are essentially no conformational changes 
between K2P2.1 I110D and the K2P2.1 I110D:Ru360 complex except for a change near 
the base of the CAP helices similar to that seen in the RuR complexes (Figure S4I). The 
Keystone inhibitor site acidic sidechains directly coordinate the Ru360 RuA and RuB 
centers (Figure 3I). Ru360 also makes van der Waals contacts to the upper part of the 
selectivity filter and part of the CAP from chain A similar to those made by RuR (cf. 
Figures 1G, 2G, and 3I). Together, these data demonstrate that Ru360 inhibits RuR-
sensitive K2Ps and reveals the common mode by which polynuclear ruthenium amines 
affect K2P channels by binding to the Keystone inhibitor site, blocking ion exit from the 
selectivity filter, and obstructing one EIP arm. 
Protein engineering creates RuR super-responders 
Because the electronegative nature of the Keystone inhibitor site is a key determinant 
of K2P channel sensitivity to polynuclear ruthenium compounds, we wanted to test 
whether increasing the electronegative character of surrounding portions of the EIP would 
also affect RuR block. To identify candidate sites, we looked for elements on the floor of 
the RuR and Ru360 binding site that made close contacts with the inhibitors. This analysis 
identified the backbone atoms of the selectivity filter outer mouth residues Asn147 and 
Asp256 as the nearest neighbors (Figures 1G, 2G, 3G, and 4A). As we cannot easily 
change the backbone atoms, we considered changing the properties of the sidechains 
from these positions. Sequence comparison of representatives from each K2P subtype 
(Figure S5A) shows that the two sites have very different conservation patterns. The 
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Asn147 site shows a range of amino acid types. This variability contrasts with the strict 
conservation at the Asp256 site. Because all K2Ps have aspartate at the 256 position 
regardless of whether or not they RuR-sensitive, we reasoned that the negatively charged 
sidechain at this site has no influence on RuR binding. By contrast, the amino acid 
diversity at the Asn147 site indicated that this site might have different properties than the 
Asp256 site. Hence, we tested whether replacing Asn147 with a negatively charged 
residue would impact K2P2.1 (TREK-1) RuR sensitivity. TEVC experiments showed that 
RuR inhibited both K2P2.1 N147D and K2P2.1 N147E (Figures 4C-F), demonstrating that 
the presence of an acidic residue at the Keystone inhibitor site is not the only means by 
which a K2P channel can acquire RuR sensitivity. Notably, there was a marked difference 
in the IC50s between the two mutants with N147E having a much greater susceptibility to 
RuR inhibition than N147D (IC50 = 0.0733 ± 0.0165 and 47.7 ± 6.3 µM for K2P2.1 N147E 
and K2P2.1 N147D, respectively) (Figures 4G-I, Table 1). Similar to RuR inhibition of other 
K2Ps, RuR block of K2P2.1 N147E was essentially voltage independent, whereas 
K2P2.1 N147D showed a mild voltage-dependence (Figures S5B-E). 
Because both N147D and N147E changes were able to confer RuR sensitivity to 
K2P2.1 (TREK-1) (Figure 4F, Table 1), we asked whether having negatively charged 
residues on both the ceiling (residue 110) and floor (residue 147) of the RuR binding site 
would result in enhanced RuR inhibition. TEVC measurements of the RuR responses of 
K2P2.1 I110D/N147D and K2P2.1 I110D/N147E revealed that both double mutants had 
similar IC50s (IC50= 0.0127 ± 0.0023 and 0.0126 ± 0.0034 µM for K2P2.1 I110D/N147D 
and K2P2.1 I110D/N147E, respectively) (Figures S5F-G, Table 1). Similar to the I110D 
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and N147E mutants, the response of both double mutant channels to RuR was essentially 
independent of voltage (Figures S5H-J). 
The IC50s values of the double mutants were an order of magnitude better than that 
of K2P2.1 I110D alone and three orders of magnitude better than K2P2.1 N147D. Hence, 
we turned to double mutant cycle analysis69,70 to assess the extent of synergy between 
the two sites with respect to RuR inhibition. This analysis uncovered a strong positive 
cooperativity for the I110D/N147D pair (DDG = -4.1 kcal mol-1) (Figure S6A). By 
contrast, the enhanced RuR response of the I110D/N147E combination resulted from 
essentially additive contributions of the two negatively charged residues (DDG = -0.3 
kcal mol-1) (Figure S6B). The fact that the two double mutant pairs do not behave 
equivalently even though both comprise two sets of acidic sidechains, together with the 
observation that there is a substantial difference in the impact of I110D versus I110E 
alone on the RuR sensitivity of K2P2.1 (TREK-1) (Figure 1E, Table 1) reinforces the idea 
that RuR molecular recognition requires both general electrostatic interactions and the 
direct coordination from the acidic sidechains. Taken together, our results indicate that 
details of these two factors tune the strength of the RuR interaction with the channel. 
Because of the largely conserved nature of the K2P architecture in the region of the CAP 
and selectivity filter26-29, installing acidic residues simultaneously at the equivalents of 
the K2P2.1 (TREK-1) Ile110 and Asn147 positions should endow any K2P of interest 
sensitive to nanomolar concentrations of RuR.  
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Discussion 
Polynuclear ruthenium compounds have been used for nearly 50 years to control the 
function of various ion channels3-20,22-25. Yet, despite this widespread application in the 
study of a multitude of diverse ion channels, there is only limited visualization of how such 
compounds might interact with and affect the function of their targets21. The K2P:RuR and 
K2P:Ru360 complexes presented here provide the first detailed structural views of how 
this class of inorganic polycations can inhibit ion channel function. The structures 
demonstrate general molecular recognition principles in which a channel uses acidic 
sidechains to coordinate both trinuclear, RuR, and dinuclear, Ru360, ruthenium amines 
through direct, multipronged electrostatic interactions. Both compounds block the flow of 
ions through the channel using a ‘finger in the dam’ mechanism that exploits the unique 
archway architecture that the K2P CAP domain creates above the K2P channel mouth 
(Figure 5A). 
K2Ps are the only potassium channel family that bears a CAP domain, an extracellular 
dimerization domain positioned directly above the channel pore26,29. The structures 
presented here show that a pair of aspartic acids located on the underside of the CAP 
archway at a site that controls the RuR response of natively-RuR sensitive K2Ps, K2P10.1 
(TREK-2) and K2P9.1 (TASK-3)4-6 and of the RuR-sensitive mutant K2P2.1 I110D 
(Figure 1E)3, create a polycation binding site, the Keystone inhibitor site. This site forms 
the primary point of interaction with a single RuR or Ru360 that plugs one arm of the 
bifurcated EIP created by the CAP domain archway (Figures 1E-F, 2E-F, 3G-H). This 
structural observation defines an unambiguous mechanism of action for how 
polyruthenium amines inhibit K2Ps, as holding a large polycation above the channel pore 
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would both physically block ion exit as well as provide an electrostatic barrier to permeant 
ion movement (Figure 5A). Ru360 a dinuclear oxo-bridged ruthenium amine inhibitor of 
the mitochondrial calcium uniporter15,59,60 that had not previously been reported to affect 
potassium channels also inhibits engineered, K2P2.1 I110D, and natively-RuR sensitive 
K2Ps, K2P10.1 (TREK-2), and K2P9.1 (TASK-3), in a manner similar to RuR (Figure 3E-F). 
Hence, even though RuR and Ru360 bind to a largely pre-formed binding site, there is 
sufficient plasticity to permit the binding of different types of polyruthenium cations. 
Consistent with a binding site positioned above the selectivity filter and outside of the 
transmembrane electric field, polynuclear ruthenium amine inhibition of K2Ps is 
independent of voltage (Figures S1E-G, S4A-B, S5B-E and H-J) and the C-type gate 
activation (Figure 2D). Together, the data define a mechanism of action in which 
polynuclear ruthenium amines inhibit K2P function by preventing ion flow out of the K2P 
selectivity filter and through the EIP (Figure 5A). 
Although many ion channels lack the extracellular archway made by the K2P CAP 
domain, the structures of the K2P:polyruthenium amine complexes reveal general 
molecular recognition principles that are likely to be shared with RuR and Ru360 sensitive 
ion channels. The requirement to have a negatively charged residue at the Keystone 
inhibitor site for RuR (Figure 1E)3-6 and Ru360 (Figure 3F) responses, together with the 
observation that inhibitor potency is proportional to the total charge (Table 1) highlights 
the importance of electrostatic interactions for recognizing ruthenium polycations. The 
multipronged direct coordination of the RuR and Ru360 ruthenium amine moieties 
(Figures 1G, 2G, and 3G) shows the important role that direct coordination by acidic 
sidechains plays in binding both compounds. The observation that equivalently charged 
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residues having different sidechain geometries, aspartate and glutamate, display 
differential effects on RuR potency at the Keystone inhibitor site (Figure 1D and Table 1) 
highlights the importance of direct ligand coordination for tuning the strength of the 
interaction with polynuclear ruthenium amines. It should be noted that K2P4.1 (TRAAK) is 
inhibited by RuR but lacks a negatively charged residue in the Keystone inhibitor site 
(Figure S1A) and binds RuR with a higher stoichiometry than observed for the K2P 
channels studied here (Table 1)3,62. These differences suggest that RuR inhibition of 
K2P4.1 (TRAAK) occurs using a mechanism different from the ‘finger in the dam’ 
mechanism. Given the importance of direct interactions between RuR and Ru360 and the 
acidic sidechains in the target channels studied here and the fact that acidic residues are 
key to the RuR sensitivity of other channels25,71, we expect that similar types of 
multipronged coordination by sidechain carboxylates are likely to contribute to the RuR 
and Ru360 block of other polynuclear ruthenium amine sensitive channels such as K2P4.1 
(TRAAK), TRPs7-14, the mitochondrial calcium uniporter (MCU)15-18, CALHM calcium 
channels19-21, ryanodine receptors22,23, and Piezo channels24,25, even if the details of 
where the inhibitor binds to the channel differ. 
K2P channels can be modulated by a number of different small molecules and lipids57. 
When placed in the context of previous structural studies of K2P modulator 
interactions27,28,56, our studies highlight an emerging picture of the complex, multisite 
structural pharmacology that contributes to the control of K2P function. The discovery of 
the Keystone inhibitor site reveals that there are at least four control sites that span from 
the inner leaflet of the bilayer to the extracellular parts of the channel through which 
exogenous molecules affect channel function (Figure 5B). These include a modulatory 
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lipid binding site in the bilayer inner leaflet28, the fenestration site residing at the 
intersection of the movable M4 transmembrane helix and the lower part of the selectivity 
filter that can be targeted by both small molecule activators and inhibitors27,56, the K2P 
modulator pocket site28, and the Keystone inhibitor site. Exploring the degree of 
conformational coupling among these modulatory sites will be important for 
understanding the extent of synergistic or antagonistic actions within the various classes 
of K2P modulators. Acquiring this type of knowledge will be crucial for creating new 
interventions that could offer exquisite control of K2P function. 
The ‘finger in the dam’ inhibitory mechanism defined here provides a blueprint for the 
development of small molecule or protein-based K2P modulators that could reach through 
the EIP to the Keystone inhibitor site. In this regard, designing compounds having 
moieties that interact with the Keystone inhibitor site but that also make contacts to 
non-conserved features of CAP exterior could yield subtype-selective modulators. 
Biologics, such as nanobodies, may be particularly suited to this type of molecular 
recognition mode. Further, given the highly conserved nature of the K2P channel 
architecture in the region of the CAP and selectivity filter26-29, the strategies we used to 
develop RuR super-responders should be applicable to other K2P subfamily members to 
create subtypes endowed with RuR sensitivity. Such RuR-sensitive channels could be 
used to dissect the roles of various K2Ps in their native physiological settings. 
Significance 
Ruthenium Red (RuR) is a trinuclear, oxo-bridged ruthenium amine polycation that 
has many biological applications, including a ~50 year legacy as an inhibitor of diverse 
classes of ion channels. RuR inhibits select members of the K2P (KCNK) family, numerous 
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TRP channels, the mitochondrial calcium uniporter, CALHM calcium channels, ryanodine 
receptors, and Piezo channels. Despite this remarkably wide range of ion cannel targets, 
there are extremely limited structural data describing how RuR binds to any ion channel 
target. Our studies show how two polyruthenium compounds, RuR and Ru360, inhibit  K2P 
channels through a ‘finger in the dam’ mechanism in which these polycations bind at a 
novel site, the ‘Keystone inhibitor site’, formed by acidic residue pair under the K2P CAP 
domain archway above the channel pore. This series of structures, together with 
functional studies, outline the molecular recognition principles that govern how RuR and 
Ru360 bind to specific sites of proteins using a mixture of electrostatics and polyvalent 
coordination by acidic sidechains. These principles are likely to control RuR and Ru360 
binding to a wide range of diverse ion channel targets. Moreover, we show that we can 
use knowledge of these factors to engineer RuR ‘super-responder’ K2Ps that have RuR 
sensitivity in the low nanomolar range. The protein engineering strategy we define should 
be generally applicable to any K2P of interest and provide a new method for dissecting the 
function of specific K2Ps in complex settings such as neurons, the brain, and the 
cardiovascular system. Together, the data define a ‘finger in the dam’ inhibition 
mechanism acting at a novel K2P inhibitor binding site. These findings highlight the 
polysite nature of K2P pharmacology and provide a new framework for K2P inhibitor 
development. 
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Materials and Methods 
Molecular Biology 
Murine K2P2.1 (TREK-1) (Gene ID 16526), K2P10.1 (TREK-2) (Gene ID: 72258), and 
K2P9.1 (TASK-3) (Gene ID: 223604) were each expressed from in a pGEMHE/pMO vector 
for two-electrode voltage clamp (TEVC) experiments as described previously28,55. A 
previously described version of murine K2P2.1 (TREK-1) in a Pichia pastoris pPicZ 
plasmid, K2P2.1(TREK-1)CRYST28,  encoding residues 21-322 and bearing the following 
mutations: K84R, Q85E, T86K, I88L, A89R, Q90A, A92P, N95S, S96D, T97Q, N119A, 
S300C, E306A, was used for structural studies. Mutants of K2P2.1 (TREK-1) and 
K2P2.1(TREK-1)CRYST were generated using site-directed mutagenesis (PFU Turbo AD, 
Agilent) and verified by sequencing of the complete gene. 
Two-electrode voltage clamp (TEVC) electrophysiology 
Xenopus laevis oocytes were harvested according to UCSF IACUC Protocol 
AN129690 and digested using collagenase (Worthington Biochemical Corporation, 
#LS004183, 0.7-0.8 mg mL-1) in Ca2+-free ND96 (96 mM NaCl, 2 mM KCl, 3.8 mM MgCl2, 
5 mM HEPES pH 7.4) immediately post-harvest, as previously reported28,55. Oocytes 
were maintained at 18°C in ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, 
5 mM HEPES pH 7.4) supplemented with antibiotics (100 units mL−1 penicillin, 100 μg 
mL−1 streptomycin, 50 μg mL−1 gentimycin) and used for experiments within one week of 
harvest. mRNA for oocyte injection was prepared from plasmid DNA using mMessage 
Machine T7 Transcription Kit (Thermo Fisher Scientific), purified using RNEasy kit 
(Qiagen), and stored as stocks and dilutions in RNAse-free water at -80°C.  
Defolliculated stage V-VI oocytes were microinjected with 50 nL of 0.1-6 ng mRNA 
  97 
 
and currents were recorded within 24-48 hours of injection. Oocytes were impaled by two 
standard microelectrodes (0.3-3.0 MΩ), filled with 3M KCl and subjected to constant 
perfusion of ND96. Currents were elicited from a -80 mV holding potential using a 500 ms 
ramp ranging from -140 to +50 mV. 
Recording solutions containing Ruthenium red (RuR) (Millipore-Sigma, R2751) and 
Ru360 (Millipore-Sigma, Calbiochem – 557440) were prepared immediately prior to use. 
RuR was weighed and dissolved directly into ND96 at 200 μM in ND96 and then diluted 
into ND96 for tested experimental concentrations. The pH of the stock solution was 
checked to ensure no change occurred. Due to its instability in aqueous solutions, Ru360 
solutions were covered with aluminum foil to minimize exposure to light and to avoid 
degradation. RuR and Ru360 were determined to be stable in recording solutions for 
duration of typical experiment length by measuring UV absorbance at 536 nm and 363 
nm, respectively, before and after length of the recording session. ML335 was 
synthesized as described previously28. ML335 recording solutions were prepared from a 
DMSO stock stored at -20oC (final DMSO concentration was 0.1%).  
Data were recorded using a GeneClamp 500B (MDS Analytical Technologies) 
amplifier controlled by pClamp software (Molecular Devices), and digitized at 1 kHz using 
Digidata 1332A (MDS Analytical Technologies). For each recording, control solution 
(ND96) was perfused over a single oocyte until current was stable before switching to 
solutions containing the test compounds at various concentrations and again allowed to 
stabilize before recording final, stabilized trace. Fractional block at the potential of interest 
was determined as !"!!!""!! in which I is the measured current, I0 is the current in the absence 
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of the test compound, and IB is the basal current derived from an average of uninjected 
oocytes (n=14). For dose-response curves, each point is an average of at least three 
oocytes recorded from at least two independent batches of oocytes. Representative 
traces and dose response plots were generated in Graphpad Prism Version 5 (GraphPad 
Software, San Diego California USA, www.graphpad.com). Inhibition IC50s were 
estimated using an auto-fitted Hill equation with a Hill coefficient = -1.0. 
Protein expression 
K2P2.1CRYST I110D was expressed as a fusion protein having in series from the 
channel C-terminus a 3C protease site, green fluorescent protein (GFP), and His10 tag as 
described previously for K2P2.1cryst28. Linearized plasmid DNA (PmeI) was introduced into 
Pichia pastoris strain SMD1163H via electroporation. Strains with highest incorporation 
were selected for on YPD plates containing 1-2 mg mL-1 zeocin. Individual colonies were 
screened using fluorescence size exclusion chromatography (FSEC)72 to identify strain 
with highest expression level as described previously28. The best FSEC candidate was 
used to inoculate a starter culture (60-120 mL) in minimal media (1% glycerol, 100 mM 
potassium phosphate pH 6.0, 0.4 mg L-1 biotin, 1X YNB from Invitrogen) supplemented 
with 1 mg mL-1 zeocin and cultured in shaker flask for 2 days at 29°C. The starter culture 
was then used to inoculate a large scale (6-12L) culture in shaker flasks containing 
minimal media without zeocin. Cells were grown at 29°C over two days in minimal media 
containing 1% glycerol. Cells were centrifuged at 3000g (6 min, 20°C) and pellet was 
resuspended in minimal induction media (100 mM potassium phosphate pH 6.0, 0.4 mg 
L-1 biotin, 1X YNB) containing 0.5% methanol. After 24 hrs, 0.5% methanol was added to 
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each flask. Cells were harvested (6000g, 20 min, 4°C) two days after induction, 
snap-frozen in liquid nitrogen, and stored at -80°C. 
Protein Purification 
Purified K2P2.1cryst I110D was obtained from preparations using 100-200g of cell mass 
cryo-milled (Retsch, MM400) in liquid nitrogen (5 x 3 min, 25 Hz). All purification steps 
were carried out at 4°C and purification conditions were similar to those previously 
reported for K2P2.1cryst28. Cell powder was solubilized at a ratio of 3 grams of cells per mL 
of lysis buffer containing 200 mM KCl, 21 mM octyl glucose neopentyl glycol (OGNG, 
Anatrace), 30 mM n-heptyl-β-D-thioglucopyranoside (HTG, Anatrace), 0.1% cholesterol 
hemisuccinate (CHS, Anatrace), 100 mM Tris-Cl, pH 8.2, 1 mM PMSF and 0.1 mg/mL 
DNaseI. Following 3 hour membrane solubilization, the sample was centrifuged at 
40,000g for 45 min at 4°C. After centrifugation, supernatant was incubated with anti-GFP 
nanobodies immobilized on CNBr-activated sepharose resin (GE Healthcare, 17-0430-
01) at a ratio of 1 mL resin per 10 g of cells and gently rotated on an orbital rocker for 3 
hours. Resin was collected in a gravity column (Econo-Pac, 1.5 x 12 cm, BioRad) and 
washed with 10 CV each, buffers A-C (A-C: 200 mM KCl, 50 mM Tris-Cl pH 8.0, 15 mM 
HTG; A: 10 mM OGNG, 0.018% CHS; B: 5 mM OGNG, 0.018% CHS; C: 3.85 mM OGNG, 
0.0156% CHS), applied in series to reduce the detergent concentration and wash away 
cell debris (30 CV total). The GFP-affinity tag was cleaved overnight on column using two 
CV of buffer C supplemented with 350 mM KCl, 1 mM EDTA and 3C protease73. Cleaved 
protein was eluted from resin with two CV of size-exclusion buffer (SEC: 200 mM KCl, 20 
mM Tris-Cl pH 8.0, 2.1 mM OGNG, 15 mM HTG, 0.012% CHS), concentrated and applied 
to a Superdex 200 (GE, 10/300) pre-equilibrated with SEC buffer. Peak fractions were 
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evaluated by SDS-PAGE (15% acrylamide) for purity, pooled and concentrated for 
crystallization. 
Crystallization, structure determination, and refinement 
Purified K2P2.1cryst-I110D was concentrated to 6 mg mL-1 before crystallization using 
hanging-drop vapor diffusion at 4oC using a mixture of 0.2 µL protein to 0.1 µL reservoir 
solution, over 100 µL reservoir of 20-25% PEG400, 200 mM KCl, 100 mM HEPES pH 8.0 
or 7.1 and 1-2 mM CdCl2. Crystals appeared within 1-2 days and grew to full size within 
2 weeks. Crystals were cryoprotected in solution containing 200 mM KCl, 0.2% OGNG, 
15 mM HTG, 0.02% CHS, 100 mM HEPES pH 8.0 or 7.1 and 1-2 mM CdCl2, with 5% 
increase in PEG400 up to final concentration of 38% before flash freezing in liquid 
nitrogen. For compound bound structures, cryoprotected crystals were also soaked in 
final cryoprotection solution containing 1 mM each RuRed, RuRed+ML335 or Ru360, 
sourced as described in TEVC methods, for at least 1 hour prior to flash freezing in liquid 
nitrogen. 
Datasets were collected at 100 K using synchrotron radiation at APS GM/CAT 
beamline 23-IDB/D Chicago, Illinois using a wavelength of 1.0332 Å, processed with 
XDS74 and scaled and merged with Aimless75. Highest resolution structures were 
obtained from crystals that were soaked with the ruthenium compounds. Structure 
determination of low resolution datasets from complexes obtained by co-crystallization 
indicated that there was no difference in the RuR position in complexes made by either 
soaking or co-crystallization. Final resolution cutoff was 3.40 Å, 3.49 Å, 3.00 Å and 3.51 
Å for K2P2.1cryst I110D, K2P2.1cryst I110D:RuR, K2P2.1cryst I110D:RuR:ML335 and 
K2P2.1cryst I110D:Ru360 structures, respectively, using the CC1/2 criterion76. K2P2.1cryst-
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I110D was solved by molecular replacement utilizing K2P4.1 (G124I) structure (PDB: 
4RUE) as search model. For compound bound structures, the K2P2.1cryst-I110D model 
was used as the molecular replacement search model. Electron density maps were 
improved through several cycles of manual model rebuilding, using COOT77, REFMAC 
(CCP4), and PHENIX78. 
Mutant cycle analysis 
Double mutant cycle analysis69,70 was carried out using the equation  " =	!##"	%&∗!##"	($)$!##"	($∗!##"	)$  in which Ω is the coupling factor70 and IC50WT, IC50X’, IC50Y’ and IC50X’Y’ 
are the IC50 values for the wild-type, each single mutant of the X-Y pair, and the double 
mutant, respectively. As wild type K2P2.1 (TREK-1) is unaffected by RuR, the free energy 
of the interaction is zero and hence, Ka and Kd = 1. Coupling energy, DDGΩ, was 
calculated as ∆∆&* = '()*" where R=1.987 cal mol-1 deg-1 and T= 298K. 
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Figure 3.1 | Functional and structural analysis of the K2P2.1 I110D:RuR complex. 
(A) Ruthenium Red (RuR) structure (B) and (C) Exemplar TEVC recordings of (B) K2P2.1 
(TREK-1) and (C) K2P2.1 I110D responses to 10 µM RuR (magenta). (D) Dose-response 
curves for K2P2.1 (TREK-1) (open white circles), K2P2.1 I110D (black), K2P2.1 I110E (red), 
and K2P2.1 I110K to RuR. (E) Structure of the K2P2.1 I110D:RuR complex. Inset shows 
the location of the RuR binding site. I110D is shown as sticks. (F) Close up view of 
K2P2.1 I110D:RuR interactions. S0 ion (cyan) from the K2P2.1 I110D structure is indicated, 
RuR is shown in space filling in panels (E) and (F). (G) LigPLOT79 diagram of 
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K2P2.1 I110D:RuR interactions showing ionic interactions (dashed lines) and van der 
Waals contacts (red) ≤5Å. 
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Figure 3.2 | Functional and structural analysis of C-type gate activated K2P2.1 
I110D:RuR complexes. 
(A) and (B) Exemplar TEVC recordings of: (A) K2P2.1 I110D/G137I (black) and in the 
presence of 10 µM RuR (magenta), and (B) K2P2.1 I110D alone (black) in the presence 
of 50µM ML335 (cyan), and in the presence of 50 µM ML335 +10 µM RuR (magenta). 
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(C) and (D) RuR dose-response curves for (C) K2P2.1 I110D/G137I (magenta), and (D) 
K2P2.1 I110D in the presence of 50 µM ML335 (cyan). Dashed lines show RuR response 
of K2P2.1 I110D from Figure 1D. (E) Structure of the K2P2.1 I110D:ML335 RuR complex. 
Inset shows the location of the RuR binding site. I110D is shown as sticks. ML335 (grey) 
is shown as space filling. (F) Superposition of RuR binding site from the 
K2P2.1 I110D:RuR (pink) and K2P2.1 I110D:ML335:RuR (magenta) RuR and RuRML 
indicate RuR from the K2P2.1 (TREK-1) I110D:RuR and K2P2.1 I110D:ML335:RuR 
structures, respectively. ML335 is shown as sticks. (G) LigPLOT79 diagram of 
K2P2.1 I110D:RuR interactions from the K2P2.1 I110D:ML335:RuR complex  showing 
ionic interactions (dashed lines) and van der Waals contacts (red) ≤5Å. 
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Figure 3.3 | Functional and structural analysis of K2P:Ru360: interactions. 
(A) Ru360 (RuR) structure. (B-D) Exemplar TEVC recordings of (B) K2P2.1 (TREK-1), 
(C)  K2P2.1 I110D, (D) K2P10.1 (TREK-2), and (E)  K2P9.1 (TASK-3) alone (black) and in 
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the presence of 90 µM Ru360 (green, teal, and olive, respectively). (F) Ru360 
dose-response curves for K2P2.1 I110D (green), K2P2.1 (TREK-1) (light green), 
K2P10.1  (TREK-2) (teal), and K2P9.1  (TASK-3) (olive). Dashed line shows RuR dose-
response for K2P2.1 I110D from Figure 1D. (G) Structure of the K2P2.1 I110D:Ru360 
complex. Inset shows the location of the Ru360 binding site. I110D is shown as sticks. 
(H) Close up view of K2P2.1 I110D (cyan), K2P2.1 I110D:RuR (pink), and 
K2P2.1 I110D:Ru360 Keystone inhibitor sites. RuR and Ru360 are shown as sticks. S0 
ion from the K2P2.1 I110D structure is shown as a sphere. (I) LigPLOT79 diagram of 
K2P2.1  I110D:Ru360 interactions showing ionic interactions (dashed lines) and van der 
Waals contacts (red) ≤5Å. 
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Figure 3.4 | Engineering K2P RuR super-responders 
(A) View through the K2P2.1 (TREK-1) CAP to the floor of the Keystone inhibitor site. CAP 
H2 helix (pink) is shown as a cartoon. RuR is shown as semi-transparent spheres. 
Surface (white) shows the top of the selectivity filter. I110D, N147, and D256 are shown 
as sticks. (B) Cartoon depiction of the elements framing the Keystone inhibitor site. 
Locations of CAP, I110D, and N147 are indicated. Selectivity filter potassium ions are 
shown as purple circles. (C-E) TEVC recordings of (C) K2P2.1 N147D alone (black) and 
in the presence of 1 µM RuR (magenta), (D) K2P2.1 N147D alone (black) and in the 
presence of 100 µM RuR (magenta)  and (E)  K2P2.1 N147E alone (black) and in the 
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presence of 10 µM RuR (magenta). (F) RuR response of K2P2.1 N147D (purple) and 
K2P2.1 N147E (orange). Dashed line shows K2P2.1 I110D response to RuR, from Figure 
1D. (G) and (H) TEVC recordings of (G) K2P2.1 I110D/N147D alone (black) and in the 
presence of 1 µM RuR (magenta), and (H) K2P2.1 I110D/N147E alone (black) and in the 
presence of 1 µM RuR (magenta). (I) RuR dose-response of K2P2.1 I110D/N147D (red) 
and K2P2.1 I110D/N147E (blue). Dashed line shows K2P2.1 I110D response to RuR, from 
Figure 1D. 
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Figure 3.5 | Mechanisms of small molecule K2P modulation 
(A) Cartoon diagram depicting the ‘finger in the dam’ mechanism of K2P inhibition by 
polynuclear ruthenium amines. Ion flow is indicated by the dashed orange lines. 
Potassium ions are shown as purple circles. (B) Polysite model of K2P modulation. 
Diagram shows structurally defined sites for K2P modulators: Keystone inhibitor site 
(magenta), K2P modulator pocket (orange)28, fenestration site (green)27,56, and modulatory 
lipid site (cyan)28. Extracellular ion pathway (EIP) and selectivity filter ‘C-type’ gate are 
indicated. CAP is outlined in blue and shows the position of the negatively charged 
residues required for the Keystone inhibitor site (sticks). 
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Figure 3.6 | S1 - K2P CAP sequences and K2P2.1 CAP mutant functional properties 
(A) CAP H2 helix sequences for the indicated K2P channels. Measured3-6 or predicted (p) 
Ruthenium Red (RuR) sensitivity is indicated. Arrow indicates the position of the RuR 
sensitivity determinant (amino acids highlighted in red). K2P2.1 I110D , K2P2.1 (TREK-1) 
AAD47569.1, K2P10.1 (TREK-2) BAF83207, K2P4.1 (TRAAK) AAI10328.1, 
K2P3.1 (TASK-1) NP_002237.1, K2P9.1 (TASK-3) NP_001269463.1, K2P5.1 (TASK-2) 
NP_003731.1, K2P1.1 (TWIK-1) NP_002236.1, K2P6.1 (TWIK-2) NP_004814.1, 
K2P16.1 (TALK-1) NP_001128577.1, K2P17.1 (TALK-2) AAK28551.1, K2P12.1 (THIK-2) 
NP_071338.1, K2P13.1 (THIK-1) NP_071337.2, K2P15.1 (TASK-5) EAW75900.1, 
K2P18.1 (TRESK) NP_862823.1. K2P15.1 (TASK-5) cannot be functionally expressed29. 
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(B) and (C) Exemplar TEVC recordings of (B) K2P2.1 I110E and (C) K2P2.1 I110K 
responses to 50 µM RuR (magenta). (D-G) Analysis of the voltage-dependence of RuR 
inhibition of K2P2.1 I110D and K2P2.1 I110E. (D) and (E) Dose-response curves 
at -20 mV (red), 0 mV (black), +20 mV (yellow), and +40 mv (purple) for (D) K2P2.1 I110D 
and (E) K2P2.1 I110E. (F) and (G) RuR IC50 (µM) as a function of voltage for (D) 
K2P2.1 I110D and (E) K2P2.1 I110E. Error bars are SEM. 
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Figure 3.7 | S2 - K2P2.1 I110D structures and structure comparisons 
(A) Superposition of K2P2.1 (TREK-1) (orange) (PDB:6CQ6)(27), K2P2.1 I110D (cyan), 
and K2P10.1 (TREK-2) (PDB:4BW5) (yellow)28. Insets show comparison of area around 
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the I110D mutation. Top, K2P2.1 (TREK-1) and K2P2.1 I110D; Bottom K2P2.1 I110D and 
K2P10.1 (TREK-2). (B) Superposition of K2P2.1 I110D (cyan) and K2P2.1 I110D:RuR 
(pink). Inset shows area around the Keystone inhibitor site. RuR is shown as sticks with 
a semi-transparent surface. (C) Exemplar Fo-Fc density (3s)(dark blue) for the K2P2.1 
I110D:RuR complex (pink). RuR is shown as sticks. (D) Close up view of K2P2.1 I110D 
(cyan) and K2P2.1 I110D:RuR (pink) showing conformational changes in the Keystone 
inhibitor site. RuR is shown as sticks with a semi-transparent surface. 
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Figure 3.8 | S3 - K2P2.1 I110D ML335 response and structure of the K2P2.1 
I110D:RuR:ML335 complex 
(A) Exemplar two-electrode voltage clamp recordings of the response of 
K2P2.1 I110D (black) to 10 µM ML335 (green). (B) ML335 dose-response curve for 
K2P2.1 I110D. EC50 = 11.8 ± 2.3 µM, matching that of K2P2.1 (TREK-1) (14.3 ± 2.7µM28). 
(C) Superposition of K2P2.1 I110D:RuR (pink) and K2P2.1 I110D:RuR:ML335 (magenta). 
I110D is shown as sticks. RuR and ML335 are shown in space filling representation. (D) 
Exemplar Fo-Fc density (3s)(dark blue) for the K2P2.1 I110D:RuR:ML335 complex 
(magenta), and (I110D, RuR, Ru360, and ML335 are shown as sticks. S1 selectivity filter 
ion is labeled. (E) Close up view of K2P2.1 I110D (cyan) and K2P2.1 I110D:RuR:ML335 
(magenta) CAP base. 
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Figure 3.9 | S4 - Ru360 inhibits K2P channels 
(A-C) Ru360 dose-response curves at -20 mV (red), 0 mV (black), +20 mV (yellow), and 
+40 mv (purple) for (A) K2P2.1 I110D, (B)  K2P10.1 (TREK-2), and (C) K2P9.1 (TASK-3). 
(D) RuR IC50 (µM) voltage-dependence for K2P2.1 I110D (black circles), 
K2P10.1 (TREK-2) (pink diamonds), and  K2P9.1 (TASK-3) (purple squares). 
(E)  Exemplar TEVC recordings of K2P9.1 (TASK-3) alone (black) and in the presence of 
10 µM RuR (dark red). (F)  K2P9.1 (TASK-3) dose-response curves for RuR (dark red) 
and Ru360 (olive) (from Figure 3F). Dashed line shows RuR dose-response for 
K2P2.1 I110D from Figure 1D. (G) Superposition of K2P2.1 I110D:RuR (pink) and 
K2P2.1 I110D:Ru360 (green). I110D is shown as sticks. (H) Exemplar Fo-Fc density 
(3s)(dark blue) for the K2P2.1 I110D:Ru360 complex (green). I110D and Ru360 are 
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shown as sticks. S1 selectivity filter ion is labeled. (I) Close up view of 
K2P2.1 I110D:Ru360 (green). K2P2.1 I110D (cyan), and K2P2.1 I110D:RuR (pink) CAP 
base. RuR and Ru360 and are shown in space filling representation. 
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Figure 3.10 | S5 - K2P selectivity filter (SF) sequences and RuR responses of K2P2.1 
SF mutants 
(A) Sequence alignment of the selectivity filter 1 (SF1) and selectivity filter 2 (SF2) 
sequences of the following human K2P channels. K2P2.1 (TREK-1) AAD47569.1, 
K2P10.1 (TREK-2) BAF83207, K2P4.1 (TRAAK) AAI10328.1, K2P3.1 (TASK-1) 
NP_002237.1, K2P9.1 (TASK-3) NP_001269463.1, K2P5.1 (TASK-2) NP_003731.1, 
K2P1.1 (TWIK-1) NP_002236.1, K2P6.1 (TWIK-2) NP_004814.1, K2P16.1 (TALK-1) 
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NP_001128577.1, K2P17.1 (TALK-2) AAK28551.1, K2P12.1 (THIK-2) NP_071338.1, 
K2P13.1 (THIK-1) NP_071337.2, K2P15.1 (TASK-5) EAW75900.1, K2P18.1 (TRESK) 
NP_862823.1. SF1 and SF2 sequence and numbers for K2P2.1 (TREK-1)cryst 
(PDB:6CQ6)28 are identical to that of K2P2.1 (TREK-1) AAD47569.1. (B-C) RuR 
dose-response curves at -20 mV (red), 0 mV (black), +20 mV (yellow), and +40 mv 
(purple) for (B) K2P2.1 N147D and (C) K2P2.1 N147E. (D-E) IC50 voltage dependence for 
(D) K2P2.1 N147D and (E) K2P2.1 N147E. (F-G) RuR dose-response curves for (F) 
K2P2.1 N147D (purple) and K2P2.1 I110D/N147D (red) and (G)  K2P2.1 I110E (orange) 
and K2P2.1 I110D/N147E (blue). Dashed lines show RuR response of K2P2.1 I110D from 
Fig. 1D. (H-I) RuR dose-response curves at -20 mV (red), 0 mV (black), +20 mV (yellow), 
and +40 mv (purple) for (H) K2P2.1 I110D/N147D and (I) K2P2.1 I110D/N147E. (J) IC50 
voltage dependence for K2P2.1 I110D/N147D (black circles) and K2P2.1 I110D/N147E 
(blue squares). Error bars are SEM. 
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Figure 3.11 | S6 - Double mutant cycle analysis 
Double mutant cycle analysis69,70 for the RuR responses of (A) K2P2.1 I110D/N147D 
and (B) K2P2.1 I110D/N147E. " =	 !##"	($)$!##"	($∗!##"	)$. as ∆∆&* = '()*" where R=1.987 cal 
mol-1 deg-1 and T= 298K. 
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Table 3.1 | IC50 values for RuR and Ru360 
 
Inhibitor Construct EC50 (µM) n 
R
uR
 
K
2P
2.
1 
(T
R
EK
- 1
) 
K2P2.1 (TREK-1) >100 3 
K2P2.1 I110D 0.287 ± 0.054 3 
K2P2.1 I110E 13.6 ± 2.7 3 
K2P2.1 I110K >100  
K2P2.1 I110D/G137I 0.154 ± 0.023 3 
K2P2.1 I110D + 50 µM 
ML335 
0.173 ± 0.021 3 
   
K2P2.1 N147D 47.7 ± 6.3** 2 
K2P2.1 N147E 0.0733 ± 0.0165 3 
K2P2.1 I110D/N147D 0.0127 ± 0.0023 3 
K2P2.1 I110D/N147E 0.0126 ± 0.0034 3 
   
O
th
er
 K
2P
s    
K2P10.1 (TREK-2) [D135]* 0.23 ± 0.06 µM 
(Braun et al., 2015) 
3 
K2P9.1 (TASK-3) [E70]* 0.114 ± 0.021 µM 3 
   
    
R
u3
60
 K
2P
2.
1 
(T
R
EK
- 1
)     
K2P2.1 (TREK-1) >100 3 
K2P2.1 I110D 11.3 ± 1.8 3 
O
th
er
 
K
2P
s     
K2P10.1 (TREK-2) [D135]* 2.8 ± 1.2 3 
K2P9.1 (TASK-3) [E70]* 15.6 ± 2.7 3 
    
 
n = number of oocytes 
Errors are SEM. 
‘*’ residue at the K2P2.1 (TREK-1) I110D equivalent position 
** Lower bound constrained to 0.2 
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Table 3.2 | Supplementary table 1 - Data collection and refinement statistics 
 K2P2.1 (TREK-1) I110D 
(PDB:6V36) 
K2P2.1 (TREK-1) 
I110D:RuR  
(PDB:6V3I) 
Data collection   
Space group P212121 P212121 
Cell dimensions   
    a, b, c (Å) 69.19/120.40/128.35 67.95/120.3/127.82 
    a, b, g (°)  90/90/90 90/90/90 
Resolution (Å) 46.7 – 3.40 (3.67  - 3.40) 46.6  - 3.49 (3.82  - 3.49) 
Rmerge 0.072 (5.87) 0.089 (3.80) 
I/s(I) 9.6 (0.5) 9.8 (0.8) 
CC1/2 0.999 (0.128) 1.000 (0.331) 
Completeness (%) 99.9 (100.0) 100.0 (100.0) 
Redundancy 6.5 (6.7) 8.8 (9.0) 
   
Refinement   
Resolution (Å) 15.00 - 3.40  15.00 – 3.49  
No. reflections 14468 13484 
   
Rwork / Rfree 28.6/31.6 26.5/32.7 
No. atoms 4124 4192 
    Protein 4066 4092 
    Ligand/ion  
K+ 
Cd++ 
Lipid 
ML335 
55 
6 
3 
46 
0 
98 
5 
3 
63 
0 
RuR 0 1 
Ru360 
Water 
 
0 
3 
0 
2 
B factors   
    Protein 227.94 191.96 
    Ligand/ion 195.40 196.35 
   
R.M.S. deviations   
    Bond lengths (Å) 0.004 0.004 
    Bond angles (°) 0.913 0.760 
Ramachandran   
    Favored (%) 94.6 93.9 
    Allowed (%) 4.8 5.1 
    Outliers (%) 0.6 1.0 
Each dataset was derived from a single crystal. 
a Values in parentheses are for highest-resolution shell.   
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Table 3.3 | Supplementary table 1 (ct’d) - Data collection and refinement statistics 
 K2P2.1 (TREK-1) 
I110D:RuR:ML335 
(PDB: 6V37) 
K2P2.1 (TREK-1) 
I110D:Ru360 
(PDB:6V3C) 
Data collection   
Space group P212121 P212121 
Cell dimensions   
    a, b, c (Å) 67.02/118.74/129.04 67.74/120.71/127.27 
    a, b, g (°)  90/90/90 90/90/90 
Resolution (Å) 46.5  - 3.00 (3.18  - 3.00) 46.4  - 3.51 (3.85  - 3.51) 
Rmerge 0.085 (2.45) 0.110 (8.64) 
I/s(I) 16.8 (1.2) 10.8 (0.4) 
CC1/2 0.996 (0.553) 1.000 (0.149) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 
Redundancy 13.2 (13.7) 13.3 (13.7) 
   
Refinement   
Resolution (Å) 14.99 – 3.00 14.98 – 3.51 
No. reflections 21051 12595 
   
Rwork / Rfree 26.7/31.4 31.0/32.6 
No. atoms 4309 4063 
    Protein 4180 3993 
    Ligand/ion  
K+ 
Cd++ 
Lipid 
ML335 
127 
5 
3 
82 
1 
68 
5 
3 
43 
0 
RuR 1 0 
Ru360 
Water 
 
0 
2 
1 
2 
B factors   
    Protein 145.60 200.63 
    Ligand/ion 150.32 182.87 
   
R.M.S. deviations   
    Bond lengths (Å) 0.003 0.002 
    Bond angles (°) 0.628 0.559 
Ramachandran   
    Favored (%) 92.5 96.6 
    Allowed (%) 6.7 3.4 
    Outliers (%) 0.8 0.0 
Each dataset was derived from a single crystal. 
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a Values in parentheses are for highest-resolution shell.   
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Table 3.4 | Supplementary table 2 - Structure Comparisons of RuR and Ru360 
complexes 
   RMSD (Å) 
    
K2P2.1 I110D  
Ve
rs
us
 
K2P2.1 (TREK-1) (6CQ6)(27) 0.575 
K2P2.1 I110D K2P10.1 (TREK-2) (4BW5)(26) 0.938 
K2P2.1 I110D  K2P2.1 I110D:RuR 0.688 
K2P2.1 I110D  K2P2.1 I110D:Ru360 0.665 
K2P2.1 I110D:RuR:ML335 K2P2.1 I110D:RuR 0.507 
K2P2.1 I110D:RuR:ML335 K2P2.1 (TREK-1):ML335 (6CQ8)(27) 0.480 
K2P2.1 I110D:Ru360 K2P2.1 I110D:RuR 0.561 
    
 
RMSDs were calculated using Ca atoms in the specified residue ranges after optimal 
translational and rotational alignment of those atoms. Calculations were performed with 
the MDAnalysis python package version 0.19.2 (78). Residue ranges include all of the 
a-helical portions of the structures as follows: K2P2.1 (TREK-1): 45-93, 96-110, 126-190, 
206-259, 268-300; K2P10.1 (TREK-2): 75-123, 126-140, 156-220, 236-289, 299-331. 
4BW5 comparison is for chains A and B from the asymmetric unit.  
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Chapter 4 : Stapled voltage-gated calcium channel (CaV) a-interaction domain 
(AID) peptides act as selective protein-protein interaction inhibitors of CaV 
function 
Felix Findeisen, Marta Campiglio, Hyunil Jo, Fayal Abderemane-Ali, Christine H. 
Rumpf, Lianne Pope, Nathan D. Rossen, Bernhard E. Flucher, William F. DeGrado, 
and Daniel L. Minor, Jr 
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Abstract 
For many voltage-gated ion channels (VGICs) creation of a properly functioning ion 
channel requires the formation of specific protein-protein interactions between the 
transmembrane pore-forming subunits and cytoplasmic accessory subunits. Despite the 
importance of such protein-protein interactions in VGIC function and assembly, their 
potential as sites for VGIC modulator development has been largely overlooked. Here, 
we develop meta-xylyl (m-xylyl) stapled peptides that target a prototypic VGIC high affinity 
protein-protein interaction, the interaction between the voltage-gated calcium channel 
(CaV) pore-forming subunit a-interaction domain (AID) and cytoplasmic b-subunit (CaVb). 
We show using circular dichroism spectroscopy, X-ray crystallography, and isothermal 
titration calorimetry that the m-xylyl staples enhance AID helix formation, are structurally 
compatible with native-like AID:CaVb interactions, and reduce the entropic penalty 
associated with AID binding to CaVb. Importantly, electrophysiological studies reveal that 
stapled AID peptides act as effective inhibitors of the CaVa1:CaVb interaction that 
modulate CaV function in an CaVb isoform-selective manner. Together, our studies 
provide a proof-of-concept demonstration of the use of protein-protein interaction 
inhibitors to control VGIC function and point to strategies for improved AID-based CaV 
modulator design. 
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Introduction 
Voltage-gated ion channels (VGICs) control electrical signaling in the brain, heart, and 
nervous system1. Many members of this protein superfamily are multi-protein complexes 
comprising both transmembrane pore-forming subunits and cytoplasmic regulatory 
subunits2. VGIC cytoplasmic subunits can exert strong control over channel function by 
conferring distinct biophysical properties to the resulting channel complex and by affecting 
channel biogenesis and plasma membrane trafficking1, 3-5. Although the importance of 
such subunits for VGIC function is well established, with the exception of a few cases6-9, 
their potential as targets for the development of agents that could control channel function 
has been largely overlooked10-12. Protein-protein interaction antagonists have been 
shown to be effective modulators of diverse protein classes13-17 but have not yet been 
developed and validated for any ion channel system. Hence, we asked whether we could 
advance this type of reagent against the exemplar VGIC high-affinity protein-protein 
interaction formed between the voltage-gated calcium channel pore-forming CaVa1 and 
cytoplasmic CaVb subunits for which there is a wealth of structural information to guide 
design18. 
High-voltage CaVs (CaV1s and CaV2s) are the principal agents of calcium influx in 
excitable cells, are vital components of the machinery that regulates muscle contraction, 
vascular tone, hormone and neurotransmitter release, and synaptic function and provide 
a prototypical example of the pivotal role of cytoplasmic subunits in VGIC function1, 19-21. 
CaV1s and CaV2s are made from at least four main components18, 22, 23: a CaVa1 pore 
forming subunit, a cytoplasmic CaVb subunit20, 21, the extracellular CaVa2d subunit24, and 
a calcium sensor protein, such as calmodulin25. The CaVa1:CaVb interaction is central to 
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the formation of properly functioning native CaVs20, 21, controls CaV trafficking to the 
plasma membrane3, 26-30, and affects a number of CaV biophysical properties including 
voltage-dependent activation and the rate of channel inactivation20, 21, 31-39. CaVa1 and 
CaVb associate through a high affinity (Kd ~nM)40-45 interaction between a short peptide 
segment on the CaV intracellular I-II loop, known as the a-interaction domain (AID), and 
a groove in CaVb termed the a-binding pocket (ABP)20, 46-49.  
CaVs are validated targets for drugs treating cardiovascular diseases, epilepsy, and 
chronic pain19, 50. Well-studied modifiers of CaV function such as small molecule drugs 
and peptide toxins largely target the pore-forming subunit19, 50-52. Because of the central 
role of the AID:ABP protein-protein interaction in CaV function, there has been an interest 
in establishing whether interfering with this interaction might provide an alternative 
strategy for CaV modulation45, 53. Previous studies suggesting that the CaVa1:CaVb 
interaction is labile54-57 and studies showing that blocking CaVb action is a productive 
means to affect CaV function8, 9 support such an approach. 
Because stapled-peptide strategies have been particularly effective at targeting 
protein-protein interactions in which one partner is single a-helix17, 58, such as in the 
AID:ABP case, we pursued the stapled-peptide strategy to develop AID-based inhibitors 
of the AID:ABP interaction and CaV function. Previously, we and others demonstrated 
that chemical crosslinking of i and i+4  cysteines could be useful for a-helical peptide 
stabilization59, 60. Here, we expand this cysteine crosslinking strategy to constrain an 
N-terminal capping motif61, 62 appended to the AID. Our studies demonstrate that stapling 
AID peptides with a meta-xylyl bridge59, 63 between two engineered cysteines creates AID 
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peptides having enhanced helical content that bind CaVb in a native-like manner. We find 
that the macrocyclic constrained cap acts as an effective means to enhance helix content 
and that importantly, the enhanced AID peptide is a potent inhibitor of CaV currents that 
causes CaVb isoform-specific inhibition of the AID:ABP interaction. 
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Results 
AID Backbone modifications increase alpha-helical content of AID 
Structural studies have shown that there is essentially no conformational change 
between the apo- and AID-bound CaVb ABP46-48. By contrast, the CaV AID peptide 
undergoes a large conformational change between an unbound disordered state and the 
CaVb-bound helical conformation45, 47, 64, 65. This binding event involves a substantial 
entropic penalty, ~-14 cal mol-1 K-1 45, that due to the essentially unchanged structure of 
the ABP, must arise from the entropic cost of ordering the AID. In order to overcome this 
problem, we pursued a chemical stabilization strategy to enhance the helical structure of 
the AID unbound state (Figure 1A). 
Previously, we and others demonstrated that introduction of m-xylyl linker between 
two cysteines (i, i+4) by thiol alkylation63 could be used to stabilize the α-helical 
conformation in peptides59, 60. This cysteine alkylation strategy has the advantage of not 
requiring unnatural amino acids. To date, all strategies for stapled peptide synthesis have 
focused on introduction of linkers along one α-helix face, an approach that can buttress 
the structure but that does not restrain the α-helix polar ends. To address this issue, we 
introduced an N-terminal capping motif61, 62 into two AID peptides, AID-CAP and AID-CEN 
(Figure 1B). This capping motif includes an NCap position serine intended to stabilize the 
structure through hydrogen bonds to the exposed amide protons at the helix N-terminus, 
an N1 position proline to act as a helix initiator, and an N3 position glutamate placed to 
contribute hydrogen bonds to the NCap serine and amide backbone (Figure 1B). In the 
case of AID-CAP, two cysteines were included to make a macrocyclic capping box 
sequence, Cys-Ser-Pro-Leu-Glu-Cys, in which the cysteine residues should allow facile 
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macrocyclization with m-xylyl bromide (Figure 1B). AID-CEN bears an unconstrained 
capping motif and a more conventional (i, i+4) crosslinking motif within the helix (K435C 
and D439C) (Figure 1B). In both peptides, cysteine positions for staple attachment were 
chosen to reside on the exposed AID surface based on structures of the CaVb-AID 
complexes in order to avoid introducing interfering interactions. 
Circular dichroism (CD) studies of AID-CAP and AID-CEN indicated that m-xylyl staple 
incorporation affected the secondary structure to different extents depending on the 
staple location (Figure 1C). The m-xylyl staple in AID-CEN caused a modest change that 
reduced the intensity of the signal at 208 nm relative to the unmodified AID. By contrast, 
AID-CAP displayed the hallmark double minima associated with α-helical structure that 
was absent in the unmodified AID peptide66 and that indicates that the N-terminal cap site 
is a potent element for stabilizing the AID helical conformation. 
X-ray crystal structures show that CaVb2a:stapled AID complexes are similar to 
native complexes 
To investigate the structural integrity of the backbone staple designs, we crystallized 
and determined the structure of AID-CAP and AID-CEN bound to a unimolecular CaVb2a 
construct previously used for extensive CaVb2a:AID thermodynamic binding studies45. 
Crystals of the AID-CAP complex grew in the H3 space group having one molecule in the 
asymmetric unit and diffracted X-rays to 1.9 Å (Table S1). Structure solution by molecular 
replacement (R/Rfree= 18.5/23.0%) revealed a CaVb2a:AID structure similar to that 
determined previously for the unconstrained AID48 (RMSDCa= 1.2 Å) (Figure 2A) except 
for a few minor differences. The CaVb2a a1 helix is longer by ten residues (Figure S1A) 
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and there is a moderate divergence in the angle of the a2 helix. This element precedes 
the disordered V2/HOOK domain and extends from the SH3 domain far from the AID 
binding site (Figure S1A) and is affected by crystal lattice contacts. Excluding the a2 helix 
from the comparison, the structures of the CaVb2a:AID- and CaVb2a :AID-CAP complexes 
are essentially identical (RMSDCa= 0.55 Å over residues 43-127, 217-273, 295-414). 
The structure of the CaVb2a:AID-CAP complex (Figure 2A) reveals that the AID-CAP 
peptide binds to the a-binding pocket (ABP) in a manner that is identical to the wild-type 
AID (Figure S1A) using the main hydrophobic anchors Tyr437, Trp440, and Ile441, and 
interactions with two buried water molecules coordinated by the sidechain of Ty437 
(Figure S1B)45-48. The m-xylyl linker connecting the iài+5 cysteines was clearly visible in 
the electron density (Figure 2B). This moiety makes no interactions with CaVb, indicating 
that its effects are only on the AID conformational properties as intended. The N-terminal 
AID-CAP residue, Cys427, adopts a non-helical conformation that occupies the 
b-backbone conformation portion of the Ramachandran plot. Subsequent residues form 
a regular a-helix. Within the m-xylyl stabilized region, the Glu431 sidechain contacts the 
backbone nitrogen of Ser428, satisfying the backbone requirement for this otherwise free 
functional group and the intention of the sequence design. The cysteine members of the 
m-xylyl staple, Cys427 and Cys432, have sidechain χ1 angles of (+60°) and meta (-180°), 
respectively, resulting in a 5.9 Å distance between the Cys427 and Cys432 sulfurs, that 
allows for unstrained connection through the meta-xylene functional group. 
We also obtained crystals of the CaVb2a:AID-CEN complex that grew in the P212121 
spacegroup, diffracted X-rays to 1.8 Å, and were solved by molecular replacement 
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(R/Rfree = 15.8/19.6%) (Figure 2C, Table S1). In this structure, CaVb2a has an extended 
C-tail (residues 417-425) (Figure S1A) but otherwise, the CaVb2a component is essentially 
unchanged from the CaVb2a core48 (RMSDCa= 0.4 Å over residues 43-127, 217-273, 
295-414) or  CaVb2a in the CaVb2a:AID-CAP complex (Figure 2C, RMSDCa = 0.4 Å over 
residues 43-127, 217-273, 295-414). As with the CaVb2a:AID-CAP complex, the AID-CEN 
backbone forms a regular a-helix and the CaVb2a:AID-CEN interaction is unaltered from 
the native structure (Figure S1B). Density for the i à i+4 m-xylyl backbone staple was 
well resolved (Figure 2D) and shows that, similar to the situation with AID-CAP, the 
m-xylyl staple plays no direct role in in CaVb binding. The cysteine anchors for the m-xylyl 
staple, Cys435 and Cys439, have sidechain χ1 angles of -180° and -161°, respectively. 
This conformation leads to a 6.5 Å distance between the Cys435 and Cys439 sulfurs. The 
~20° deviation from the regular low energy conformers of Cys439 suggests that there is 
a small energetic cost for liganding the anchor atoms at a 6.5 Å distance. Comparison of 
the N-terminal capping motifs in the CaVb2a:AID-CAP and CaVb2a:AID-CEN complexes 
shows that the designed hydrogen bond network among the NCap, N2, N3, and N4 positions 
is well formed in the presence of the AID-CAP m-xylyl staple (Figure S1C). This network 
is also present in the unconstrained capping motif in AID-CEN, but has longer hydrogen 
bonds and slightly different interactions for Glu431 (Figure S1D). Together, the structural 
data demonstrate that the m-xylyl staple is compatible with the helical conformation of the 
AID and in the case of AID-CAP helps to organize the N-terminal capping motif. 
AID helix staples lower the entropic cost of ligand binding 
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Having determined that the backbone staples are able to affect AID helix content 
(Figure 1) and are structurally compatible with the CaVb-AID interaction (Figure 2), we 
used isothermal titration calorimetry (ITC) to investigate whether the AID staples impacted 
binding thermodynamics. Experiments measuring CaV1.2 AID binding to the CaVb2a core 
yielded an affinity in good agreement with prior measurements Kd = 6.6 ± 2.0 nM vs. 
5.3 nM45 (Figure 3A, Table 1). This binding reaction is driven by a favorable enthalpic 
component (DH = -15.6 ± 2.4 kcal mol-1) that is opposed by a large entropic cost 
(DS = -16.7 ± 6.0 cal mol-1 K-1) that most likely results from the requirement to reduce the 
degrees of freedom of the highly disordered ligand upon binding. 
ITC measurements with AID-CEN and AID-CAP revealed that both peptides bind 
CaVb2a with affinities similar to wild type AID, 5.2 ± 1.5 nM and 5.1± 1.6 nM, respectively 
(Figure 3B and C, Table 1) but that incorporation of the m-xylyl moiety affects the 
thermodynamic binding parameters of the CaVb2a:AID interaction. Consistent with the 
incorporation of the m-xylyl staple and decrease in random coil as seen by CD (Figure 1), 
the entropic cost of complex formation was reduced relative to the wild type for both 
stapled peptides (DS = 2.2 ± 0.5 and -4.6 ± 4.1 cal mol-1 K-1 for AID-CEN and AID-CAP, 
respectively). However, this reduction of the unfavorable entropic component was offset 
by a binding enthalpy reduction (DH= -10.2 ± 0.1 and -12.3 ± 1.4 kcal mol-1, AID-CEN and 
AID-CAP, respectively). Because neither m-xylyl staple contributes to the AID:ABP 
interaction, and there are no obvious changes in ABP interaction site contacts (Figure 
S1A and S1B), this result appears to be an example of enthalpy-entropy compensation67 
and may originate in the loss of some of the favorable enthalpy of helix formation68 due 
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to the pre-ordering of the helical structure in the unbound state. Even though the effects 
of enthalpy-entropy compensation left the binding affinity unaffected, the data 
demonstrate that the inclusion of the staple was effective at reducing the disorder of the 
unbound AID as designed. 
Stapled AID peptides compete with mutant but not wild-type CaV1.2:CaVb2a 
complexes 
Because AID-CAP and AID-CEN had similar affinities for CaVb but the AID-CAP had 
the highest amount of helical structure, we focused on testing whether AID-CAP could 
affect CaV function. CaVb binding to the pore-forming CaVa1 subunit AID is known to cause 
clear changes to channel gating properties, such as the extent and speed of inactivation 
and the channel activation potential (V1/2)20, 45, 64. We were concerned that the tight 
interaction between CaVa1 and CaVb subunits might be difficult to compete with an 
exogenous peptide, particularly because the CaV1.2:CaVb2a interaction has been shown 
to be long-lived unless it is weakened by ABP-AID interface mutations69. Hence, we first 
performed competition experiments using a CaVa1 subunit bearing an AID mutation that 
lowers the CaVb affinity by ~1000 fold (Y437A, Kd = 5.3 vs. 5263 nM for wild-type and 
Y437A, respectively45). To test the ability of AID peptides to interfere with CaV function, 
we measured the response of pre-assembled, functional, plasma membrane CaV 
complexes expressed in Xenopus oocytes to competitor peptides (Figure 4), similar to 
the approach we used previously to uncover the direct competition between calcium 
sensor proteins on CaVs70. Two principal inactivation processes govern CaV function, 
voltage-dependent inactivation (VDI)71, 72 and calcium-dependent inactivation (CDI)25, 72, 
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73. Because VDI is essentially absent with CaVb2a20 and CDI requires CaVb64, we 
measured CDI over the course of 30 minutes post-injection to monitor functional 
consequences of AID peptide injection on CaVb2a containing channels (Figure 4). 
One functional signature of the interaction of CaV1.2 with CaVb2a is the extent and 
speed of inactivation, which are more complete and faster, respectively, in the presence 
of CaVb2a (Table 2). Prior to peptide injection, CaV1.2-Y437A:CaVb2a channels were 
essentially functionally identical to wild-type CaV1.2:CaVb2a channels (Table 2). Within 30 
minutes of injection of 400 µM AID or AID-CAP peptides, we observed substantial and 
similar changes from both peptides with respect to the extent of channel inactivation 
300 ms after activation (ti300) (ti300 decreased from 64.9 ± 1.9% to 44.8 ± 2.1% and 
65.5 ± 1.3% to 43.1 ± 3.7% for AID and AID-CAP, respectively) (Figure 5 A-C). In fact, at 
30 minutes after peptide injection, the extent of inactivation was indistinguishable from 
CaV1.2 expressed in the absence of CaVb (ti300 = 47.9 ± 1.2%, 44.8 ± 2.1%, and 43.1 ± 3.7 
%, for no CaVb, AID (30’), and AID-CAP (30’), respectively), suggesting that the peptides 
had interfered completely with CaVb binding. By contrast, injection of an AID mutant 
peptide in which the three most important residues for binding to CaVb were mutated to 
alanine (Y437A/W440A/I441, termed ‘HotA’45) showed no specific effects on fractional 
inactivation and had effects indistinguishable from water injection (Figure 5) (ti300 
decreased from 68.8 ± 1.0% to 63.7 ± 1.3% and 67.2 ± 1.9% to 59.8±2.6% for HotA and 
water, respectively, Figure 5 and Table 2). In addition to the ti300 changes, the fraction of 
the fast inactivation component decreased after injection of either AID or AID-CAP to 
levels similar to CaV1.2 expressed without a CaVb subunit (Figure 5C). 
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A second functional signature of the interaction of CaVb2a with CaV1.2 is a 
hyperpolarizing shift of ~10 mV in the channel activation (V1/2 = 18.1 ± 1.0 mV and 
8.1 ± 1.2 mV, for CaV1.2 without and with CaVb2a, respectively, Table 2). In CaV1.2 
Y437A:CaVb2a channels, competition with both the AID and AID-CAP peptides reduced 
this effect of CaVb on channel activation (V1/2  = 15.1 ± 2.0 mV and 16.9 ± 1.0 mV, for AID 
and AID-CAP, respectively) (Figure 5D, Table 2). By contrast, oocytes co-expressing 
CaV1.2-Y437A:CaVb2a that were injected either with water or the HotA peptide did not 
show any changes in gating characteristics. These observations are consistent with the 
notion that AID and AID-CAP peptide injection counteracted the effect of CaVb2a on the 
voltage-dependency of channel activation and suggest that the observed effects arise 
from disruption of the CaV1.2:CaVβ2a interaction. 
Recordings from CaV1.2-Y437A:CaVb2a expressing oocytes challenged by AID or 
AID-CAP also showed consistently higher rundown, compared to recordings from water 
or HotA peptide injected oocytes (Figure 5E and Table 2). This increased rundown may 
reflect some enhanced internalization of channel once the CaV1.2:CaVb interaction is lost 
or possible inhibition of the formation of new complexes. Subtraction of the water-injected 
baseline revealed that the AID and AID-CAP induced rundown of Imax reached steady 
state on the timescale of minutes (Figure 5F) and that the AID-CAP peptide was more 
potent than the unstapled wild-type. The rundown process could be well fit by a single 
exponential (Figure 5F) (t= 5.3 ± 0.9 and 4.1 ± 0.4 min for AID and AID-CAP, 
respectively). All of the observed characteristic changes caused by AID and AID-CAP 
injection are consistent with a disruption of the CaV1.2:CaVb2a interaction. 
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Given that the AID-CAP peptide performed better than the AID, we next asked 
whether AID-CAP could compete with CaVb2a bound to an unaltered channel. Contrasting 
the results with CaV1.2-Y437A, the effects of 400 µM AID-CAP injection into wild-type 
CaV1.2 expressing oocytes were not different from the effects seen with water or similar 
concentration injections of HotA on CaV1.2-Y437A:CaVb2a. Increasing the injected 
AID-CAP concentration to 2.8 mM did not cause functional effects that were different from 
the negative controls with the exception of inducing a slight increase in channel rundown 
(Figure 6). Thus, unlike the situation in which the AID:ABP interaction is weakened by the 
Y437A mutation in the CaV1.2 a1-subunit AID, native CaV1.2:CaVb2a complexes appear 
to be sufficiently stable to resist kinetic competition by the injected peptides. 
Stapled AID peptides compete with functional CaV1.2/CaVb3 complexes in 
oocytes 
CaVb2a bears an N-terminal palmitoylation site74 that anchors it to the plasma 
membrane making it different from other CaVb isoforms. This membrane tethering should 
increase the effective concentration75 of the AID:ABP interaction and could thwart the 
ability of AID peptides to compete with the native AID:ABP interaction. To test this idea, 
we examined whether AID and AID-CAP peptides could affect wild-type CaV1.2 
co-expressed with non-palmitoylated isoform CaVb3 that shares a conserved structure 
and ABP-AID interface with CaVb2a45, 46. By strong contrast with the CaV1.2:CaVb2a results 
(Figure 6), injection of AID or AID-CAP into oocytes expressing CaV1.2:CaVb3  channels 
at the maximal peptide concentration that was ineffective against CaV1.2:CaVb2a channels 
(2.8 mM, Figure 7) resulted in a striking change of the channel properties compared to 
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the control HotA peptide (Figure 7A, Table 2). Over the course of 30 minutes, competition 
with AID and AID-CAP decreased the extent of inactivation (ti300 from 73.4 ± 2.0% to 49.8 
± 1.9% and from 73.2 ± 1.5% to 48.3 ± 4.1%, respectively, Figure 7B), prolonged t of 
inactivation (Figure 7C), and shifted the activation V1/2 (from 6.3 ± 1.6 to 20.5 ± 2.8 mV 
and from 10.4 ± 2.2 to 21.0 ± 2.0 mV for AID-CAP and AID, in contrast to HotA, from 
6.7 ± 2.9 to 8.6 ± 3.3 mV Figure 7D). Following injection with both the AID-CAP and AID 
peptides there was also a clear change in channel inactivation kinetics, which changed 
from one having two components to a monoexponential process. Similar to the 
CaV1.2-Y437A:CaVb2a experiments, injection of AID and AID-CAP peptides resulted in 
strongly increased current rundown, consistent with a loss of active channels on the 
plasma membrane (Figure 7E). All of these functional changes are consistent with the 
near complete disruption of the CaV1.2a1:CaVb3 interaction and are absent in currents 
from oocytes expressing CaV1.2:CaVb3 challenged with the HotA peptide. The nearly 
similar performance of the AID and AID-CAP peptides matches their comparable affinities 
for CaVb (Figure 3 and Table 1). There is a slight advantage for the AID-CAP version that 
suggests that the peptide staple improves the performance of the peptide in a cellular 
setting (Figure 7). 
Measurement of the time constant for the loss of channels by fitting to a single 
exponential yields t = 5.3 ± 0.7 min and 4.6 ± 0.4 min for AID-CAP and AID, respectively. 
These values are notably similar to those measured for CaV1.2 Y437A:CaVb2a complexes 
(5.3 ± 0.9 min and 4.1 ± 0.4 min, respectively, Figure 7F) and are within a factor of three 
of the reported koff for dissociation of purified CaV2.2 I-II loop peptide and CaVb2b (t = 2.1 
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min)44. These observations, together with the similar binding properties of all AID and 
CaVb isoforms45 suggest that the functional effects we observe are driven by dissociation 
of CaVb from the channel. Taken together, our data demonstrate that it is possible to use 
exogenous AID peptides to disrupt CaVa:CaVb interactions. Differences in the labile 
nature of the AID:CaVb interaction lead to CaVb isoform-specific effects even though the 
target AID:ABP interactions are strictly conserved. 
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Discussion 
The function, regulation, and biogenesis of many VGIC superfamily members rely on 
the formation of protein-protein complexes between VGIC pore-forming and cytoplasmic 
subunits1, 76. Well-studied examples of how this class of protein-protein interactions can 
affect VGIC biophysical properties and cellular targeting have been elaborated for CaV1 
and CaV2 pore-forming subunits with CaVb20, 23, 45-48 and the interaction of Kv1 and Kv4 
voltage gated potassium channels with either Kvb4, 77 or KChIPs4, 78, respectively. In 
particular, application of CaV1 AID peptides to channel containing membrane patches has 
been reported to modulate CaV1.2 channels in a manner consistent with competition of 
the CaVa1:CaVb interaction55 and comprehensive structural and functional studies have 
shown that cortisone can modulate Kv1 channels by competing with the KV1-Kvb 
interaction6, 7. These initial studies suggest that antagonists of the protein-protein 
interactions between pore-forming and cytoplasmic VGIC components may offer an 
alternative strategy to control channel function that contrasts the classical approaches 
that target the pore-forming subunit19, 50-52, 79. 
Targeting protein protein-interactions remains challenging14, 16. Nevertheless, notable 
successes have been made in developing protein-protein interaction antagonists for a 
variety of cellular targets such as Bcl-XL, p53, and estrogen receptors14-17. Despite the 
many successes with intracellular targets, there has been little successful development 
reported regarding VGIC protein-protein interaction antagonists. Two studies have 
detailed the search for compounds that would affect CaVa-CaVb53 and Kv4-KChIP 
interactions80, but neither validated the reported compounds as authentic protein-protein 
interaction antagonists. Given such lack of progress targeting ion channel protein-protein 
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interactions as a point of pharmacological intervention and questions about the degree to 
which interactions between pore-forming and cytoplasmic subunits may be labile there 
has been reasonable skepticism about whether targeting such interactions can be a 
viable strategy to control channel function in cellular settings12, 19. Our studies here, using 
a classic paradigm for cytoplasmic subunit modulation, that of the CaVa1:CaVb interaction, 
now validate the concept of using protein-protein antagonists to control a VGIC and 
should open a path to further development of this type of strategy to control channel 
function. 
Protein-protein interactions involving the binding of an a-helix to a partner protein 
represent one of the most attractive architectures for protein-protein interaction antagonist 
development15 as the interaction surface is limited and there are a variety of strategies 
for improving the properties of the a-helical partner. The AID:ABP interaction presents an 
example of this sort of interaction in an ion channel complex. The a-helical element of the 
complex, the AID, lacks structure in its unbound state45, 47, 64, 65 and binds to a well-defined 
CaVb cleft, the ABP,  that undergoes minimal conformational change46-48. Because 
a-helix stabilization strategies have proven successful for targeting many protein-protein 
interactions mediated by a similar general architecture15 and the binding energy of the 
AID:ABP is focused into a hotspot in the center of the AID helix45, we reasoned that 
pursuing a stapled peptide strategy58 to enhance the stability of the AID helix, might 
provide a first step in the development of CaVb-directed inhibitors of CaV function. 
Incorporation of an m-xylyl staple, a strategy used previously to stabilize the protease 
inhibitor calpastatin59 and b-catenin60, enhanced AID helix formation when placed at 
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either N-terminal (AID-CAP) or central (AID-CEN) positions (Figure 1C). The AID-CAP 
configuration proved superior for inducing helical content. We attribute this effect to the 
stabilization of an engineered helix cap by the m-xylyl staple (Figure S1C) and the 
importance of helix nucleation81, 82. Our crystallographic studies show that neither m-xylyl 
staple position altered the way the AID peptides bind CaVb (Figure 2). As anticipated, 
m-xylyl staple incorporation reduced the entropic penalty of CaVb binding (Table 1) in a 
manner consistent with reduction of disorder in the unbound AID. Nevertheless, despite 
this effect, lack of interference of the staples with CaVb complex formation, and lack of 
conformational change in the CaVb ABP, there was a concomitant reduction in the large 
enthalpic gain of complex formation that resulted in no measurable change in 
CaVb binding affinity between the unconstrained and stapled AIDs (Table 1). Such 
entropy-enthalpy compensation effects are not uncommon in protein-ligand recognition 
and design efforts67. In the case of the stapled AIDs, the ordering of the helical 
conformation may have traded away some of the gain in favorable enthalpy associated 
with the formation of helical backbone interactions68 that would otherwise be associated 
with the binding reaction. The structural information obtained here should enable 
strategies using other crosslinking sites or the combination of multiple staples to provide 
a path towards more efficacious peptide-based CaVa:CaVb protein-protein interaction 
inhibitors. Notably, even in the absence of affinity enhancement effects, the helical staples 
may offer advantages, as our cell-based assays indicated that the stapled peptide 
outperformed the unstapled AID (Figures 5 and 7). Hence, there may be multiple layers 
of benefit to helix stabilization in a cellular context that go beyond the effects on binding 
affinity. 
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Two challenges to targeting the AID:ABP interaction are competition with a nanomolar 
native interaction45 and the fact that the AID:ABP interface comprises well-conserved 
interactions among the isoforms of both partners45. Despite these challenges, our 
functional studies showed that injection of either wild-type AID or AID-CAP into Xenopus 
oocytes expressing CaV1.2-Y437A:CaVb2a or CaV1.2:CaVb3 channel complexes resulted 
in biophysical changes that were consistent with loss of CaVb modulation and binding. 
Such changes were absent for CaV1.2:CaVb2a channels in which the CaVb component is 
anchored to the membrane via palmitoylation74. The biophysical parameter changes were 
also accompanied by a reduction of channels at the cell membrane as indicated by the 
changes in the Imax parameter. Notably, such changes could also be observed for 
CaV1.2:CaVb2a, although to a lesser extent than with CaV1.2-Y437A:CaVb2a or 
CaV1.2:CaVb3, suggesting that the peptides may not only affect channels at the 
membrane, but may inhibit the formation or membrane incorporation of newly assembled 
channels or may influence channel destruction by the ERAD system30. Interestingly, the 
time constants measured for the Imax changes are close to the intrinsic dissociation rates 
reported for the AID-CaVb interaction44 and suggest that some of the competitive effects 
of the peptides may be governed by the intrinsic dissociation rates of CaVb from the pore-
forming subunit. Together, our data demonstrate that the AID:ABP interaction can be 
targeted effectively in a cellular context. Importantly, despite the high similarity in the 
residues that contribute to the AID:ABP interface and the corresponding similar 
interaction affinities for AID-CaVb pairs45, our findings show that it is possible to achieve 
some degree of isoform selective specificity. This selectivity appears to originate in factors 
outside of the ABP-AID interface that contribute to the diverse functional effects of the 
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different CaVb isoforms, that likely affect how CaVb engages the channel, and that are 
related to the CaVb off rate. Thus, our studies with stapled AID peptides show that it is 
possible to antagonize a paradigmatic protein-protein interaction central to VGIC function, 
for CaV current regulation and achieve specificity between different CaVb isoforms. 
VGICs have well-established important roles in the generation of bioelectrical signals 
in excitable tissues such as brain, heart, and muscle1 and also have an emerging set of 
‘non-classical’ roles in insulin secretion83, cancer84-86, and gene regulation87, 88. Because 
of these diverse functions and a general lack of specific means for controlling channel 
function, there remains a need to develop new molecular tools that can be used to 
probe VGIC biology51, 89, 90. Due to the importance of protein-protein interactions 
between pore-forming and cytoplasmic VGIC subunits for the biogenesis and trafficking 
of many VGICs, further development of such VGIC protein-protein interaction 
antagonists may open new means to study the dynamics of channel complexes, the 
steps associated with channel assembly, and the roles of these processes in native 
settings excitable tissues such as muscles and neurons. 
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Materials and Methods 
Molecular Biology 
Human CaV1.2 (a1C77, GenBank Z34815), human CaV1.2-Y437A, rat CaVb2a 
(GenBank NM_053851), CaVb3 (GenBank NM_001101715), and CaVa2d-1 (GenBank 
NM_00182276) were used for two-electrode voltage clamp experiments in Xenopus 
oocytes. For constructing CaV1.2-Y437A, the mutation in position 437 of CaV1.2 was 
introduced by SOE-PCR (Splicing by Overlap-PCR). Briefly, the I-II loop cDNA sequence 
of CaV1.2 was PCR amplified with overlapping mutagenesis primers in separate PCR 
reactions using pcDNA3.1-CaV1.2 as template. The two separate PCR products were 
then used as templates for a final PCR reaction with flanking primers to connect the 
nucleotide sequences. This fragment was then HpaI/PpuMI digested and cloned into the 
respective sites of pcDNA3.1-CaV1.2. 
Protein expression and purification 
CaVb2a expression and purification were done as previously described45. For complex 
formation with stapled peptides, 155 uM CaVb2a in buffer A (150 mM KCl, 1mM TCEP 
pH7.4, 10 mM HEPES/KOH pH 7.4) was mixed with an equal volume of peptide in buffer 
A, creating a molar ratio of protein:peptide of 1:1.2. Unbound peptide was removed using 
a Superdex200 HR10/30 gel filtration column run in buffer A. The CaVb2a/peptide complex 
was concentrated (Amicon filter, MWCO 10 kDa) to 8 mg/ml as determined by 
absorbance91. 
Peptide synthesis and purification 
All the AID peptides were synthesized using an automated peptide synthesizer 
(0.1 mmol scale). Fmoc-solid phase peptide synthesis was employed on Chemmatrix 
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Rinkamde resin (substitution level: ~0.5 mmol/g). Deprotection was performed with 20% 
4-methyl piperidine in DMF and coupling reactions were done in a mixture of Fmoc-amino 
acid (5 eq), HCTU (4.95 eq), and DIPEA (10eq) in DMF at 70 oC for 5 min. The peptide 
was cleaved from the resin by treatment with the cleavage cocktail (TFA: EDT: thioanisole 
= 95:2.5:2.5) and the crude product was obtained by cold ether precipitation after removal 
of TFA. The crude peptide was purified by reverse phase (RP)-HPLC C4 column and 
lyophilized. 
 Peptide crosslinking 
Peptide crosslinking was performed as described previously 59. Briefly, a solution of 
cysteine containing peptide (0.1 mM) was incubated with TCEP(1.5eq) in NH4HCO3 buffer 
(100 mM, pH=8.0) for 30 min. Then m,m’-dibromoxylene solution (2 or 3 eq, 1 mM in 
DMF) was added and stirred at room temperature. The reaction progress was monitored 
by mass spectrometry. When the reaction is complete, the reaction mixture was 
quenched by 1M HCl solution to acidic pH (pH 3 or 4) and purified by RP-HPLC.  
Crystallization and Refinement 
The CaVb2a/ASPL complex was crystallized by hanging drop vapor diffusion at 4°C by 
mixing equal volumes of protein in buffer A and well solution containing 1.5-1.7 M 
(NH4)2SO4, 5 mM b-mercaptoethanol and 0.1 M HEPES, pH 7. The CaVb2a/CSPE 
complex was crystallized by hanging drop vapor diffusion at 4°C by mixing equal volumes 
of protein in buffer A and well solution containing 34-37 % PEG400, 0.1 M MgCl2 and 
0.1 M MES, pH 6.3. After flash-freezing in well solution plus 20% glycerol, diffraction data 
were collected at Beamline 8.3.1 (Advanced Light Source, Lawrence Berkeley National 
Laboratories), indexed using MOSFLM 7.0.492 and scaled using SCALA93. Molecular 
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replacement with PHASER94 using a model derived from 1T3S yielded starting phases. 
The initial model was improved by iterative cycles of manual building in COOT95 and 
refinement against native data using Refmac596. TLS-tensors were added in the final 
cycle of refinement. Data collection and final model refinement statistics are summarized 
in Table S1. 
Circular Dichroism 
Circular dichroism spectra were measured in a 2 mm path length quartz cuvette 
(Hellma), 50 mM KCl and 10 mM KH2PO4/K2HPO4, pH 7.3 using an Aviv Model 215 
spectropolarimeter (Aviv Biomedical) equipped with a peltier temperature controller. 
Wavelength scans from 320 to 190 nm were taken at 4ºC. Each point was determined in 
triplicate from the same sample and subtracted by the average of a triplicate buffer scan. 
Each sample was checked for purity by HPLC. Molar ellipticity was calculated as follows: 
 = 100(∆m)/Cnl, where ∆m is the CD signal in millidegrees after buffer subtraction, C is 
the millimolar peptide concentration, n is the number of residues in the peptide, and l is 
the cuvette path length in centimeters.  
Isothermal Calorimetry 
Titrations were performed at 15ºC using a VP-ITC Microcalorimeter (MicroCal). 
Samples were dialyzed overnight at 4°C (Slide-A-Lyzer, 2 kDa molecular weight cut-off, 
Thermo Scientific) against 150 mM KCl and 10 mM K-phosphate, pH 7.3. After 30’ 
centrifugation at 40,000 rpm at 4 °C, protein concentrations were determined by 
absorbance at 280 nm91. All samples were degassed for 5’ prior to loading into the 
calorimeter. CaV1.2 CaVb2a core at a concentration of 2 μM was titrated with 20 μM 
modified or unmodified AID peptide with one 4 μl injection followed by 29 injections of 10 
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μl titrant. To correct the baseline either heat of dilution from titrations of injectant into 
buffer was subtracted. Data were processed with MicroCal Origin 7.0 using a single site 
binding model. 
Electrophysiology 
Details of two-electrode voltage clamp have been described previously64. In short, 
linearized cDNA was translated into capped mRNA using the T7 mMessenger kit 
(Ambion). 50 nl of a mRNA mixture containing an equimolar ratio of CaVa1 and CaVa2d-1, 
and a lower amount of CaVb were microinjected into Xenopus oocytes 48-72 hours prior 
to recording. After injection the oocytes were kept at 18°C in ND96 medium supplemented 
with penicillin (100 U ml-1) and streptomycin (100 µg ml 1). Prior studies established that 
with injections of an equimolar ratio of CaVa1 and CaVb RNA there is an excess of free  
CaVb64. To avoid an excess of free CaVb in the cytoplasm the optimal CaVa1/CaVb RNA 
ratio was determined for each RNA preparation. Different CaVa1/CaVb molar ratios were 
titrated for every RNA preparation and the highest CaVa1/CaVb RNA ratio at which the 
channel currents displayed the same extent and speed of  inactivation as oocytes injected 
with equimolar ratio of CaVa1/CaVb used for peptide injection experiments (1:10 to 1:100 
for CaVb2a:CaV1.2; 1:1 for CaVb3:CaV1.2). 
For experiments that involved peptide injections into oocytes, 5 minutes before the 
first recording, 50 nl of a mixture of 0.1M BAPTA and the test substance (peptide or water) 
was injected. Recording solutions contained 40 mM Ca(NO3)2, 50 mM NaOH, 1 mM KOH, 
and 10 mM HEPES, adjusted to pH 7.4 using HNO3. Electrodes were filled with 3 M KCl 
and had resistances of 0.3-2.0 MW. Leak currents were subtracted using a P/4 protocol. 
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Currents were analyzed with Clampfit 8.2 (Axon Instruments). All results are from at least 
two independent oocyte batches. The ti300 values were calculated from normalized 
currents at +20 mV and represent the percentage of inactivation after 300 milliseconds. 
Inactivation t values at +20 mV, Gmax, Ka, V1/2, and Vrev were calculated as described64. 
Statistical analysis 
Data are expressed as mean ± S.E.M. Statistical differences between samples were 
determined using One-way Analysis of Variance or Kruskal-Wallis One Way Analysis of 
Variance on Ranks (when data were not normally distributed), and Two-way Analysis of 
Variance associated with a Holm-Sidak post-hoc test when needed. A value of p < 0.05 
was considered significant. 
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Figure 4.1 | Backbone staples increase AID helical content  
A, Schematic showing the conformational ensemble of the native AID (top) versus the 
desired effect of incorporating the m-xylyl backbone staple. B, AID, AID-CAP and 
AID-CEN peptide sequences. The capping box residues are highlighted in red. Underline 
denotes m-xylyl linker crosslinking positions. C, Circular dichroism spectra of AID (black), 
AID-CAP (blue) and AID-CEN (orange) at 70 µM and 4°C. 
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Figure 4.2 | Crystal structures of CaVb2a:stapled peptide complexes  
A, Structure of the CaVb2a:AID-CAP complex. CaVb2a (cyan) is shown in surface 
rendering. AID-CAP (deep teal) is shown as a cartoon having sidechains shown as sticks. 
Locations of the AID-CAP and ABP, nucleotide kinase (NK) and SH3 domains of CaVb2a 
are indicated. B, 2Fo-Fc electron density (1.0 σ) for the AID-CAP m-xylyl staple. Select 
AID-CAP residues are indicated. C, Structure of the CaVb2a:AID-CEN complex. CaVb2a 
(yellow orange) is shown in surface rendering. AID-CEN (orange) is shown as a cartoon 
having sidechains shown as sticks. Locations of the AID-CEN and ABP, nucleotide kinase 
(NK) and SH3 domains of CaVb2a are indicated. D, 2Fo-Fc electron density (1.0 σ) for the 
AID-CEN m-xylyl staple. Select AID-CAP residues are indicated. 
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Figure 4.3 | Backbone modifications decrease entropic cost of CaVb2a binding 
Exemplar ITC titrations for A, 20 µM AID into 2 µM CaVb2a. B, 20 μM AID-CEN into 2 μM 
CaVβ2a core and C, 20 μM AID-CAP-peptide into 2 μM CaVb2a. 
  
  180 
 
 
 
Figure 4.4 | Schematic of AID peptide competition experiment  
Xenopus oocytes expressing CaV channels (complexes of CaV1.2 (black lines), CaVb 
(purple), CaVa2d (grey lines), and CaM (red) (left) are injected with AID-CAP peptide at 
t=0 and initial channel properties are recorded using two-electrode voltage clamp. Panels 
show two possible outcomes. Resistant complexes have no changes in channel 
biophysical properties (orange vs. black lines). Labile channel complexes in which the 
AID competitor peptide can capture released CaVb leaving an unoccupied I-II loop 
(purple) show biophysical changes. For simplicity, changes in channel current amplitude, 
an additional possible outcome for labile complexes, is not depicted. 
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Figure 4.5 | AID-CAP affects CaV1.2Y437A:CaVb2a channels  
A, Exemplar normalized ICa traces at a test potential of +20 mV for Xenopus oocytes 
expressing CaV1.2-Y437A:CaVb2a channels recorded after injection of water, 400 µM 
HotA, 400 µM AID-CAP, or 400 µM AID at the indicated post-injection times. Grey curves 
at times 10, 15, 20, 25, and 30 minutes show initial 5 minute response. B, Fractional 
inactivation after 300 ms (ti300) and C, A1, the relative amplitude of the fast inactivation 
component for CaV1.2-Y437A:CaVb2a currents as a function of post-injection time for 
water (inverted black triangles), 400 µM HotA (red squares), 400 µM AID (maroon 
triangles), or  400 µM AID-CAP (blue circles). D, Change in half maximal activation 
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potential (ΔV1/2) between recordings at 5 and 30 minutes post-injection. E, Imax(t)/Imax(5min) 
and F, Imax(t)/Imax(5min) normalized to Imax(t)/Imax(5min) of HotA injection as a function of 
post-injection time. Symbols are as in ‘B’ and ‘C’. Lines in ‘F’ show fit to I(t) = A exp (−t/τ) 
+ C (exponential) or I(t) = mt + C (linear), where I is the recorded current, A is the 
amplitude of the loss of current (for exponential fit), m is the slope factor (linear fit), an C 
is the residual current after 30 minutes. Results for AID and AID-CAP are statistically 
different from HotA in all panels (P<0.001). AID and AID-CAP results are not statistically 
different from each other except in panels 5E and 5F where (P<0.001). 
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Figure 4.6 | CaV1.2:CaVb2a channels resist AID-CAP modulation  
A, Exemplar normalized ICa traces at a test potential of +20 mV for Xenopus oocytes 
expressing CaV1.2:CaVb2a channels recorded after injection of water, 400 µM HotA, 400 
µM AID-CAP, or 2.8 mM AID-CAP at the indicated post-injection times. Grey curves at 
times 10, 15, 20, 25, and 30 minutes show initial 5 minute response. B and 
C, post-injection values of B, Fractional inactivation after 300 ms (ti300) and C, A1, the 
relative amplitude of the fast inactivation component for CaV1.2-Y437A:CaVb2a currents 
as a function of post-injection time for water (inverted black triangles), 400 µM HotA (red 
squares), 400 µM AID-CAP (blue circles) or 2.8 mM AID-CAP (teal triangles). D, Change 
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in half maximal activation potential (ΔV1/2) between recordings 5 and 30 minutes post-
injection. E, Imax(t)/Imax(5min) and F, Imax(t)/Imax(5min) normalized to HotA njection as a function 
of post-injection time. Symbols are as in ‘B’ and ‘C’. Lines in ‘F’ show fit t to I(t) = A exp 
(−t/τ) + C (exponential) or I(t) = mt + C (linear), where I is the recorded current, A is the 
amplitude of the loss of current (for exponential fit), m is the slope factor (linear fit), an C 
is the residual current after 30 minutes. There are no statistically significant differences in 
the results shown in the panels, except for 6E and 6F where the AID-CAP 2.8 mM results 
are statistically significant from Hot A (P = 0.034). 
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Figure 4.7 | AID-CAP affects CaV1.2:CaVb3 channels  
A, Exemplar normalized ICa traces at a test potential of +20 mV for Xenopus oocytes 
expressing CaV1.2:CaVb3 channels recorded after injection of 4 mM HotA, 2.8 mM AID-
CAP, or 2.8 mM AID at the indicated post-injection times. Grey curves at times 10, 15, 
20, 25, and 30 minutes show initial 5 minute response. B and C, post-injection values of 
B, Fractional inactivation after 300 ms (ti300) and C, t, the fast inactivation time constant 
of CaV1.2:CaVb3 currents as a function of post-injection time for 4 mM HotA (red squares), 
2.8 mM AID (maroon triangles), or  2.8 mM AID-CAP (blue circles). D, Change in half 
maximal activation potential (ΔV1/2) between recordings 5 and 30 minutes post-injection. 
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E, Imax(t)/Imax(5min) and F, Imax(t)/Imax(5min) normalized to HotA injection as a function of 
post-injection time. Symbols are as in ‘B’ and ‘C’. Lines in ‘F’ show fit to I(t) = A exp (−t/τ) 
+ C (exponential) or I(t) = mt + C (linear), where I is the recorded current, A is the 
amplitude of the loss of current (for exponential fit), m is the slope factor (linear fit), an C 
is the residual current after 30 minutes. Because of the switch in inactivation behavior, to 
facilitate comparisons, values from monoxponential fits of the channel kinetics were used 
for ‘C’. Results for AID and AID-CAP are statistically different from HotA in all panels 
(P<0.001 for Panels 7B, 7E and 7F; P<0.05 for Panels 7C and 7D). AID and AID-CAP 
results are not statistically different from each other except in panels 7C, 7E, and 7F 
where (P<0.001). 
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Figure 4.8 | S1 - Structures of CaVb2a:stapled peptide complexes.  
A, Superposition of CaVb2a:AID-CAP (cyan), CaVb2a:AID-CEN (yellow orange), and 
CaVb2a:AID (firebrick) (1T0H)1 complexes shown as wireframe. First and last CaVb2a 
residues in each structure are labeled and are as follows: CaVb2a:AID-CAP, Ala31 and 
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Ser414; CaVb2a:AID-CEN Ala39 and Thr425; and CaVb2a:AID, Arg41 and Asn416. N- and 
C- termini representing the maximal respective termini are indicated. Locations of CaVb2a 
SH3 and NK (also known as GK) domain are indicated. AID-CAP (deep teal), AID-CEN 
(orange), and AID (red) peptides are labeled. Dashed lines denote loop regions lacking 
electron density. B, Close-up view of AID-ABP interaction from the superposition in ‘A’. 
AID peptides are shown as wireframe. Hotspot residues, Tyr437, Trp440, and Ile44148,45, 
are shown as sticks and are labeled. Buried water molecules, Wat1 and Wat2, are shown 
and colored according to the parent structure. CaVb2a from each complex is shown as a 
cartoon. Surface (white) is from the CaVb2a:AID structure (1T0H) 48. C, and D, Close up 
view of the N-terminal capping motif residues in the C, AID-CAP, and D, AID-CEN 
structures. Sidechains and identities for N-cap positions N’, Ncap, N1, N2, N3, and N4 are 
shown. Hydrogen bonds in the N-terminal capping motif and distances are shown. 
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Table 4.1 | AID peptide:CaVb2a thermodynamic binding parameters 
 
AID 
peptide n Kd (nM) N 
∆H (kcal 
mol-1) 
∆S (cal mol-
1 K-1) 
Kd / Kd CaV1.2 
AID 
Cav1.2 
AID 3 6.6 ± 2.0 0.94 ± 0.07 -15.6 ± 2.4 -16.7 ± 6.0 1 
AID-CEN 2 5.2 ± 1.5 1.05 ± 0.03 -10.2 ± 0.1 2.2 ± 0.5 0.79 ± 0.33 
AID-CAP 3 5.1 ± 1.6 1.02 ± 0.10 -12.3 ± 1.4 -4.6 ± 4.1 0.77 ± 0.34 
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Table 4.2 | CaV1.2 inactivation parameters and GV relationship 
 
 ti300 (%) A1 (%) t1 (ms) A2 (%) 
 
CaV1.2:CaVb2a 68.4 ±1.1 49.4 ±1.9 25.4 ±1.2 21.3 ± 1.2 
CaV1.2-Y437A:CaVb2a 66.0 ± 3.2 51.6 ± 3.7 31.2 ± 4.6 22.5 ± 3.9 
CaV1.2:CaVb3 75.9 ± 1.1 70.3 ± 0.9 59.8 ± 2.5  
  59.9 ± 1.9 33.9 ± 3.0 25.4 ± 1.6 
CaV1.2, no CaVb 47.9 ± 1.2 26.8 ± 3.6 75.5 ± 10.3 48.4 ± 4.8      
C
a V
1.
2 -
Y4
37
A:
C
a V
β 2
a water 5 min 67.2 ± 1.9 51.9 ± 2.2 28.0 ± 1.5 19.7 ± 1.2 
water 30 min 59.8 ± 2.6 42.6 ± 2.6 31.6 ± 2.9 23.7 ± 1.6 
HotA, 5 min 68.8 ± 1.0 54.0 ± 1.2 33.2 ± 1.4 20.0 ± 1.3 
HotA, 30 min 63.7 ± 1.3 47.2 ± 1.2 34.5 ± 1.7 22.0 ± 1.0 
AID-CAP, 5 min 65.5 ± 1.3 52.7 ± 1.3 32.9 ± 1.7 18.8 ± 1.1 
AID-CAP, 30 min 43.1 ± 3.7 24.8 ± 3.2 52.8 ± 8.2 38.2 ± 3.0 
AID, 5 min 64.9 ± 1.9 48.5 ± 1.8 35.0 ± 1.5 24.1 ± 1.6 
AID, 30 min 44.8 ± 2.1 24.5 ± 3.0 53.3 ± 14.4 31.0 ± 1.9       
C
a V
1.
2:
C
a V
β 2
a 
water 5 min 60.8 ± 1.0 40.0 ±1.1 34.6 ± 3.9 27.1 ± 0.8 
water 30 min 58.1 ± 1.4 38.3 ± 2.5 37.3 ± 3.0 27.1 ± 2.0 
HotA, 5 min 66.8 ± 0.3 47.5 ± 1.0 28.4 ± 0.7 24.6 ± 1.0 
HotA, 30 min 62.1 ± 0.2 44.4 ±0.8 33.5 ± 2.3 24.7 ± 0.6 
AID-CAP 400 μM, 5 min 63.7 ± 1.9 41.6 ± 2.5 33.0 ± 2.3 28.9 ± 1.8 
AID-CAP 400 μM, 30 min 57.1 ± 1.6 33.1 ± 2.0 35.0 ± 1.7 28.6 ± 2.0 
AID-CAP 2.8 mM, 5 min 64.6 ± 1.3 52.4 ± 3.1 29.2 ± 3.3 19.3 ± 2.2 
AID-CAP 2.8 mM, 30 min 62.4 ± 2.6 48.1 ± 5.5 30.7 ± 6.0 27.3 ± 1.3       
C
a V
1.
2:
C
a V
β 3
 
HotA, 5 min 79.2 ± 2.2 79.7 ± 2.3 63.0 ± 2.4  
  61.0 ± 2.4 38.5 ± 1.5 27.9 ± 0.8 
HotA, 30 min 77.0 ± 2.9 78.0 ± 2.7 71.4 ± 4.6  
  56.5 ± 2.0 42.9 ± 4.4 30.0 ± 1.4 
AID-CAP, 5 min 73.2 ± 1.4 75.9 ± 1.2 76.2 ± 4.2  
  57.8 ± 1.2 48.0 ± 3.7 42.0 ± 8.3 
AID-CAP, 30 min 48.3 ± 4.1 66.3 ± 5.0 188.7 ± 30.2  
  ND ND ND 
AID, 5 min 73.4 ± 2.0 76.9 ± 3.1 62.6 ± 7.6  
  54.0 ± 2.7 40.0 ± 5.2 34.1 ± 1.4 
AID, 30 min 49.8 ± 1.9 65.0 ± 4.0 118.2 ± 11.0  
  ND ND ND 
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Table 4.3 | CaV1.2 inactivation parameters and GV relationship (ct’d) 
  
 t2 (ms) Imax V1/2 N  
CaV1.2:CaVb2a 159.6 ± 8.4 -0.411± 0.054 8.1 ± 1.2 25 
CaV1.2-Y437A:CaVb2a 177.3 ± 10.9 -0.816 ± 0.237 7.5 ± 1.4 6 
CaV1.2:CaVb3  -0.964 ± 0.008 5.5 ± 1.4 20 
 312.0 ± 47.7    
CaV1.2, no CaVb 348.3 ± 41.4 -0.245 ± 0.028 18.1 ± 1.0 14 
  
   
C
a V
1.
2-
Y4
37
A:
C
a V
β 2
a water 5 min 170.5 ± 6.3 -0.722 ± 0.092 7.8 ± 1.3 5 
water 30 min 200.5 ± 13.8 -0.430 ± 0.075 11.1 ± 1.2 5 
HotA, 5 min 212.5 ± 16.4 -1.001 ± 0.153 4.7 ± 1.4 18 
HotA, 30 min 197.9 ± 10.1 -0.578 ± 0.064 7.1 ± 1.1 18 
AID-CAP, 5 min 212.6 ± 18.6 -1.016 ± 0.122 5.4 ± 1.4 16 
AID-CAP, 30 min 469.8 ± 160.1 -0.156 ± 0.022 16.9 ± 1.0 15 
AID, 5 min 251.5 ± 16.1 -0.883 ± 0.111 2.9 ± 1.7 10 
AID, 30 min 304.0 ± 50.9 -0.242 ± 0.021 15.1 ± 2.0 10 
   
   
C
a V
1.
2:
C
a V
β 2
a 
water 5 min 222.8 ± 31.6 -1.344 ± 0.248 9.1 ± 1.8 5 
water 30 min 227.3 ± 12.1 -0.785 ± 0.074 11.6 ± 0.7 5 
HotA, 5 min 185.7 ±2.1 -0.734 ± 0.110 10.5 ± 1.5 3 
HotA, 30 min 209.5 ± 13.2 -0.531 ± 0.098 9.0 ± 0.5 3 
AID-CAP 400 μM, 5 min 215.8 ± 13.2 -0.966 ± 0.154 9.2 ± 1.5 8 
AID-CAP 400 μM, 30 min 209.7 ± 9.3 -0.555 ± 0.132 13.0 ± 1.7 8 
AID-CAP 2.8 mM, 5 min 172.5 ± 23.4 -0.984 ± 0.142 7.2 ± 0.7 5 
AID-CAP 2.8 mM, 30 min 172.2 ± 25.9 -0.465 ± 0.079 10.4 ± 0.7 5  
  
   
C
a V
1.
2:
C
a V
β 3
 
HotA, 5 min  -0.932 ± 0.041 6.7 ± 2.9 5 
 256.8 ± 10.8   5 
HotA, 30 min  -0.577 ± 0.069 8.6 ± 3.3 5 
 241.1 ± 14.6   5 
AID-CAP, 5 min  -0.889 ± 0.135 6.3 ± 1.6 6 
 639.1 ± 238.3   6 
AID-CAP, 30 min  -0.081 ± 0.023 20.5 ± 2.8 6 
 ND    
AID, 5 min  -0.860 ± 0.096 10.4 ± 2.2 7 
 354.4 ± 119.2   7 
AID, 30 min  -0.116 ± 0.010 21.0 ± 2.0 7 
 ND    
 
Data are expressed as mean values ± SE. τ values were determined at a holding potential 
of +20 mV (see Materials and methods). ti300 denotes percent inactivation at 300 ms. Imax 
is the maximal current amplitude. V1/2 values for CaV1.2 and mutants were determined 
with calcium as the charge carrier. Data were fit using the equation I = Gmax * (Vm − 
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Vrev)/(1 + exp (V1/2 − Vm)/Ka), where I is the measured peak current at each Vm, Gmax is 
the maximal macroscopic conductance, Vm is the test potential, Vrev is the reversal 
potential, V1/2 is the midpoint of activation, Ka is the slope factor29, and ND, a value not 
determined. Italic lines highlight double exponential fit values for CaVβ3 experiments. 
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Table 4.4 | Supplementary Table 1 -  Crystallographic data collection and 
refinement statistics 
  
 CaVβ2a link:AID-CAP CaVβ2a link:AID-CEN 
Data Collection   
Space group H3 P212121 
Cell dimensions a/b/c (Å) 82 / 82 / 163 55 / 62 / 130 
a/b/g (°) 90 / 90 / 120 90 / 90 / 90 
Resolution (Å) 50 – 1.90  (2.00-1.90) 50 – 1.80 (1.89 – 1.80) 
Rsym (%) 13.7 (>100%) 7.9 (>100%) 
I / σ I 4.7 (0.4) 8.7 (0.6) 
Correlation Coefficient 0.993 (0.152) 0.998 (0.338) 
Completeness (%) 96.5 (97.0) 94.7 (77.8) 
Redundancy 3.4 (2.6) 3.9 (3.7) 
Unique reflections 31133  39617 
Wilson B-factor 32.8 20.2 
     
Refinement   
Rwork / Rfree (%) 18.5 / 23.0  15.8 / 19.6 
No. of chains in AU 2 2 
No. of protein atoms 2367 2531 
No. of ligand atoms 41 9 
No. of water atoms 374 457 
RMSD bond lengths (Å) 0.0073 0.0207 
RMSD angles (°) 1.193 1.900 
Ramachandran 
best/disallowed regions (%) 
97.6 / 0.0 98.0 / 0.0 
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